Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer by Cmiljanović, Nataša
  
Development of Novel, Potent and Selective Small 
Molecular Weight PI3K/mTOR Inhibitors for the 
Treatment of Cancer 
 
Inauguraldissertation 
 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der  
Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
von 
 
Nataša Cmiljanović 
aus 
Serbien 
 
Basel 2011 
 
 
 
Natasa Cmiljanovic 2
 
 
 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von  
 
Prof. Dr. Bernd Giese 
Prof. Dr. Edwin Constable 
 
Basel, den 22.06.2010 
Prof. Dr. Eberhard Parlow 
Dekan 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Of all the frictional resistance, the one that 
most retards human movement is ignorance; the 
friction which results from ignorance can be 
reduced only by the spread of knowledge and 
the unification of the heterogeneous elements of 
humanity. No effort could be better spent." 
Nikola Tesla 
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1. Introduction 
The desire to provide appropriate medications dates back to the origin of human beings, when 
diseases were cured by using mainly plant extracts. Generally, far in the past the efforts invested in 
finding new drugs were based on intuition and empirical observation. From the pharmaceutical 
point of view, the period to 1800s is called the age of botanicals, while natural product extracts, 
particularly those derived from botanical species, provided the main source of folk medicine. 
However, over the last two centuries, progress in understanding human biology and new technology 
has dramatically changed the approach to finding drugs. During and especially in second half of 
nineteenth century, development of pharmaceutical companies contributed to the rapid progress of 
drug development. Also, synthesis of the first synthetic pharmaceutical drug, aspirin occurred in the 
latter half of the nineteenth century. First half of the twentieth century provided the production of 
vitamins, antibiotics and unification of various scientific disciplines that led to the development of 
new technologies and reducing of gap in knowledge. The second half of twentieth century is 
characterized by linking new technologies with understanding of the human body functioning and 
the structure of DNA, allowing new approaches to drug improvement. Further expansion of 
computing technology, improving of instrumentation and examination the causes of diseases helped 
to the further progression of science. Eventually, emerging of genetic engineering and 
biotechnology in the late nineties led to rational drug design. Following development of 
combinatorial chemistry based on the rapid synthesis of a large number of different but structurally 
related molecules in order to produce some potentially biologically active compounds has also 
influenced the acceleration process of drug development. Practically, the end of the twentieth 
century provided an abundant source of medicinal information due to the incredibly rapid 
development of the computer technology, the existence of more powerful pharmaceutical 
companies and expansion of knowledge in the field of human biology. Thanks to that efficient 
methods for finding new drugs have been enabled. The beginning years of the new millennium 
continued to improve in drug discovery based on state-of-the art chemistry and chemical genetics, 
new advances in biology, enzyme-based molecular syntheses, proteomics and genomics, 
recombinant biomolecules, high-throughput screening, and gene and cell therapy [1], [2]. 
 
The usual process of drug discovery consists from several crucial stages on their way from research 
laboratories to the market (Figure 1). It starts with identifying cellular and genetic factors that play a 
role in specific diseases. Once a target is identified, the next step involves discovery of some 
suitable drug candidates that can block or activate a desired target [3]. The most commonly used 
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methods in finding the promising drug candidates, with possibility to test a large number of 
different compounds in a short way, using robotics, data processing, control software, liquid 
handling devices and sensitive detectors in order to identify active compounds are high-throughput 
screening (HTS) methods. 
 
Figure 1. Overview of the most important stages in drug discovery and development process [4]. 
 
Found active compounds, so-called hits are subject of further optimization and modification in aim 
of creating a lead structure. This lead will then be further optimized via a medicinal chemistry 
project, resulting in one or two compounds which will be proposed for early drug development 
phase, referring to establish an initial safety profile of drug. In next proof of concept step and phase 
I trial, drug for a first time is given to human in order to confirm a mechanism of action, examine a 
safety, determine appropriate dosing and identify side effects. Phase II studies are designed to 
determine effectiveness and further study the safety of the candidate drug, by testing on a larger 
number of people (100-300). Phase III studies include even more detailed testing of efficacy and 
safety with several hundreds to thousands of volunteer patients. After a process of approving the 
drug by regulatory authorities, a new drug can be made commercially available to patients. Post-
approval studies test a marketed drug in new age groups or patient types and focusing on previously 
unknown side effects or related risk factors in order to accomplish better effectiveness and safety 
[4]. The process of launching drug to the market takes an average of 10 to12 years and roughly 900 
million dollar costs [3]. 
 
Each year is estimated that 10.9 million people worldwide are diagnosed with cancer and there are 
6.7 million deaths from the disease [5]. In the last decades, extreme interest in finding more 
effective treatments against cancer is continuously growing (Figure 2). Therefore, one of the most 
competitive and challenging fields in medicinal chemistry is cancer research. In recent years, 
phosphoinositide 3-kinases (PI3Ks) have become extremely attractive target of industry and the  
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Figure 2. Accumulated numbers of published papers where wortmannin was used as a PI3K inhibitor [6]. 
 
academy as well due to their possibility to modulate diverse biological process such as cell survival, 
growth and metabolic control by influencing many human diseases including allergy, inflammation, 
metabolic diseases and cancer [6]. This contributed to the development of a numerous PI3K 
inhibitors and many of them have established the potential usefulness as therapeutics for treatment 
of cancer. Several of them have already entered clinical trials. Currently two of the main interests in 
medicinal chemistry are: research of new, more active and selective inhibitors and the optimization 
of known compounds, as well as improving their pharmacodynamic and pharmacokinetic 
properties. 
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2. Theoretical Background 
2.1. Phosphoinositide 3-Kinases 
The phosphoinositide 3-kinases (PI3Ks) belong to a family of lipid kinases, which are implicated in 
signal transduction pathways and modulation of fundamental cellular activities such as cell growth, 
proliferation, differentiation, motility, survival and metabolism. The biochemical function of PI3Ks 
is the phosphorylation of the 3’-OH position of the inositol ring of PtdIns(4,5)P2, leading to 
PtdIns(3,4,5)P3, which is involved in a variety of cell signal cascades as second messenger [7]. The 
involvement of PI3Ks in such important biological processes can lead in case of their deregulation 
to development of various diseases including diabetes, thrombosis, inflammatory and autoimmune 
diseases as well as cancer [8], [9]. 
 
At the moment there have been eight different PI3Ks identified, categorized into III classes, 
according to their structural features and in vitro lipid substrate specificity [6]. Additionally there is 
a class IV of PI3Ks, comprised from PI3K-related proteins such as mTOR, DNA-PKcs, ATM, ATR, 
SMG-1 and TRRAP [10]. 
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Scheme 1. Schematic representation of PI3K functionality: Phosphorylation of the 3-hydroxyl position of the inositol 
ring of PtdIns(4,5)P2 leads to PtdIns(3,4,5)P3. 
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2.1.1. Class I PI3Ks 
 
The class I PI3Ks is the most extensively studied class within lipid kinases family due to its 
association with tumorgenesis, inflammation, cardiovascular and metabolic diseases. Therefore 
their activation and biological function is best understood among all PI3K classes. This class is 
divided into two subclasses IA and IB based on their regulatory subunit and upstream activator. 
There are three isoforms in Class IA, namely PI3K, PI3Kβ and PI3K, with the respective p110 
catalytic subunit bound to the p85 regulatory subunit. Class IB PI3K consists of catalytic subunit 
p110γ and a regulatory subunit p101 or p84 [6]. In vitro they are capable to convert PtdIns to 
PtdIns-3-P, PtdIns-4-P to PtdIns(3,4)P2, and PtdIns(4,5)P2 to PtdIns(3,4,5)P3, but in vivo substrate is 
PtdIns(4,5)P2. Activation of Class IA PI3Ks is caused by diverse receptor tyrosine kinases, while 
Class IB PI3Ks is activated by G-Protein Coupled Receptors (GPCRs). This activation leads to the 
production of PtdIns(3,4,5)P3, which recruits proteins containing pleckstrin-homology (PH)-
domains as protein kinase B (PKB/Akt). Activation of PKB/Akt by their phosphorylaton causes 
further phosphorylation of many proteins (involved in various cellular processes), regulating their 
activity in positive or negative manner [6], [11]. 
 
Catalytic subunits 
 
Regulatory subunits 
 
Figure 3. Catalytic and regulatory subunits of class I PI3Ks [6] 
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The activation of the PI3K pathway is negatively regulated by the action of two phosphoinositide 
phosphatases. The SH2-domain-containing inositol phosphatase (SHIP), hydrolyzes PtdIns(3,4,5)P3 
to PtdIns(3,4)P2 and phosphatase and tensin homolog (PTEN) reverses PtdIns(3,4,5)P3 to 
PtdIns(4,5)P2. The most frequent aberrations of PI3K signalling are loss or decreasing of PTEN 
function and mutations in PI3Kα. Loss of PTEN function is usually a late step in tumour 
progression, occurring in advanced tumour stages [6], [12], [13], [14]. 
 
2.1.2. Class II PI3Ks 
 
This class of large (170-200 kDa) enzymes comprises three catalytic isoforms (C2α, C2β, and C2γ) 
and no regulatory proteins. In vitro, class II PI3Ks preferentially phosphorylates PtdIns and PtdIns-
4-P to form PtdIns-3-P and PtdIns(3,4)P2, respectively. The relevancy of class II PI3Ks by in vivo 
processes is still under investigation. The distinct feature of class II PI3Ks is the C-terminal C2 
domain, which is Ca2+ insensitive due to the lack of a conserved aspartate residue. Their mode of 
action is still poorly understood and no adaptor molecules have been identified yet [6]. 
 
2.1.3. Class III PI3Ks 
 
Class III PI3Ks is capable to phosphorylate specifically PtdIns to PtdIns-3-P. The only one member 
of Class III PI3Ks is Vps34, which is in human cells associated with a regulatory subunit p150. 
Vps34 was first identified in a Saccharomyces cerevisiae (budding yeast) and has been shown to 
play an essential role in the trafficking of proteins and vesicles. In recent years a lot of attention was 
given to the requirement of Vsp34 in the induction of autophagy in nutrient, amino acids, as well as 
glucose-deprived cells [6]. 
 
2.1.4. Class IV PI3Ks 
 
The PI3Ks related proteins of class IV are high molecular enzymes with a catalytic core similar to 
PI3Ks. As already mentioned Class IV includes the protein mTOR, DNA-PKcs, ATM, ATR, SMG-
1 and TRRAP, which might be involved ether in cell growth control, genome transcriptome 
surveillance or DNA damage responses [6]. 
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2.2. PI3K Inhibitors 
Twenty years ago was discovered association of PI3K enzymatic activity with viral oncoproteins. 
During the next period, understanding about biological role of these enzymes has developed 
rapidly. Today, it is known that PI3Ks are involved in many vital cell functions and their 
deregulation is connected to development of various disorders. Since PI3Ks are shown to be 
important target in cancer as well as other disease, interest in development of PI3K inhibitors has 
significantly increased. The elucidation of PI3Kγ crystal structure, free and in a complex with ATP, 
wortmannin, LY294002 and other kinase inhibitors has accelerated further drug design. The 
development of PI3K inhibitors as potential therapeutic agents has made a great leap forward in the 
past several years. Several promising PI3K inhibitors have entered into clinical trials for cancer 
therapy and other diseases. Recently, researchers started to believe that treatment with an isoforme 
specific inhibitor might lead to reduction of side effects without loss of efficiency. However, the 
advantage in using isoform specific inhibitors is still under investigation. The following chapter 
presents an overview of some natural and synthetic PI3K inhibitors from the public domain, their 
mechanism of action and biological function. 
 
2.2.1. Natural PI3K Inhibitors 
 
Wortmannin (1) is a fungal metabolite, which was first isolated from Penicillium wortmanni in 
1957 by Brian and co-workers as an anti-inflammatory agent [15], while its structure was elucidated 
15 years later by Petcher and co-workers [16]. Wymann and co-workers have identified 
wortmannin (1) as a potent PI3K inhibitor against Class I, II and III PI3Ks as well as other related 
PI3K kinases [17]. Interestingly, unlike most known kinase inhibitors, wortmannin (1) inhibits 
PI3K in an ATP-non competitive manner by covalent binding with PI3K. The mechanism of PI3K 
inhibition was elucidated by the group of Prof. Matthias P. Wymann in 1996, basing on formation 
of an enamine after nucleophilic attack of Lys-802 residue of PI3K to the C-20 position of 
wortmannin. This enamine is in equilibrium with an imine (Schiff base), which is relatively stable 
at physiological pH, but is easily hydrolyzed under acidic conditions [18]. SAR studies of 
wortmannin (1) demonstrated that furan ring is essential for its activity and modifications of the 
electrophilicity of furan ring lead to serious changes in inhibitor activity [6]. Wortmannin (1) is low 
nanomolar inhibitor (IC50 ~ 5 nM), which has shown anti tumour effect both in vitro and in vivo. 
However, the liver toxicity, poor solubility and low stability have limited wortmannin (1) for 
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therapeutic use, but still wortmannin (1) has been widely used for investigating of diverse signal 
transduction processes involving PI3K [19]. 
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Scheme 2. Mechanism of PI3K inhibition by wortmannin (1). The nucleophile Lys-802 in PI3Kα (Lys-833 in PI3Kγ) 
within the ATP binding pocket attacks the furan ring of wortmannin (1) at C20, resulting in stable wortmannin-PI3K 
adduct (2) [6] 
 
Other natural compounds with PI3K inhibition activity are demethoxyviridin (3), liphagal (4) and 
resveratrol (5). Demethoxyviridin (3) was isolated from Nodulisporium hinnuleum and inhibits 
PI3Ks at low molecular concentrations with similar reaction mechanism as wortmannin, due to the 
identical furan ring system [20], [21]. Liphagal (4) was extracted from the sponge Aka coralliphaga 
and can inhibit PI3Kα and PI3Kγ, whereas the inhibition of PI3Kα already appears at 10-fold lower 
concentrations (0.1 vs. 1.0 μM) [22]. Resveratrol (5) is a plant hormone isolated for the first time in 
1940 from the roots of Veratrum grandiflorum. The production of resveratrol by grapevines is one 
of the plant’s defence mechanisms against environmental stress, such as pruning or attack by a 
microorganism. Current studies indicate that resveratrol inhibits class IA PI3K by displacing ATP, 
also it is shown that resveratrol is absorbed rapidly into the body, meaning that the molecule 
reaches the bloodstream fast and is on a hand to act on cells [23], [24]. 
 
 
Figure 4. Chemical structures of natural PI3K inhibitors: demethoxyviridin (3), liphagal (4) and resveratrol (5). 
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2.2.2. Synthetic First Generation of PI3K Inhibitors 
 
LY294002 (6) as a first synthetic PI3K inhibitor was synthesized by Lilly in the early nineties [6], 
with a chemical structure modified from quercetin, a compound which was previously demonstrated 
to inhibit PI3K as well as various protein kinases [25], [26]. Compared to wortmannin (1), 
LY294002 (6) has a 500-fold higher IC50 value (1.4 μM) for class I PI3Ks, but the advantage of 
better chemical stability. The structure of LY294002 (6) in complex with PI3Kγ has been elucidated 
by X-ray crystallography and it was shown that the morpholine oxygen forms a hydrogen bond with 
the backbone amide of Val-882. This interaction is shared by most current PI3K inhibitors as well 
as ATP. Further experiments revealed that modification of the morpholine group in LY294002 (6) 
leads to a decrease in inhibitor activity. Additional interactions occur with Lys-833, Met-804, Trp-
812 and Met-953 [27]. LY294002 (6) also showed both anti-angiogenic activity and antitumor 
efficacy in vivo. However, dermal toxicity together with poor solubility, low bioavailability and 
poor inhibitor activity prevented enter of LY294002 (6) to the clinical trial [28], [29]. 
 
 
Figure 5. Chemical structures of the synthetic first generation inhibitors: LY294002 (6) and TGX-221 (7). 
 
TGX-221 (7), which is structural derivative of LY294002 (6), is able to inhibit selectively the 
PI3Kβ isoform in vitro. The inhibition potency of TGX-221 (7) to PI3Kβ is approximately 1000-
fold over those observed for PI3Kα and PI3Kγ and about 20 fold over PI3K. Administration of 
TGX-221 (7) showed a favorable antithrombotic effect by eliminating occlusive thrombus 
formation without prolonging bleeding time [30]. 
 
IC87114 (8) is a first PI3K-specific inhibitor that inhibits PI3K with an IC50 of 0.5 μM, 58-fold 
more potently than PI3Kγ, and over 100-fold more potently than PI3Kα and PI3Kβ [31]. Originally, 
IC87114 (8) was used for investigations against inflammation and autoimmune diseases [32], but 
recently, there have been reported anti-leukemia activities of IC87114 (8) [33]. Derivatization of 
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IC87114 (8) led to new inhibitors such as PIK-39, PIK-293 and PIK-294. Molecular modelling of 
PIK-39 (9) and IC87114 (8) in complex with PI3Kγ showed that the adenine moiety of these 
molecules interacts with Val-882 and Glu-880 within the ATP bonding pocket. It was also found 
that PIK-39 (9) is able with its own ligand conformation to induce a conformational switch of Met-
804, opening a novel hydrophobic pocket. Further optimizations of PIK-39 (9) led to PIK-294 (10) 
that is also able to induce the conformational switch of Met-804, which makes PIK-294 (10) 
selective to PI3K. Additionally, PIK-294 (10) is able to fill with its phenol ring the hydrophobic 
“affinity” pocket of the enzyme leading to a 60-fold increase in inhibitor activity [34]. 
 
 
Figure 6. Chemical structures of the synthetic first generation inhibitors: IC87114 (8), PIK-39 (9), PIK-294 (10). 
 
 
A. PIK-39 B. PIK-294 
  
Figure 7. A) Crystal structure of isoform-selective PI3K inhibitor PIK-39 (9) bound to p110γ; B) predicted binding 
mode for PIK-294 (10), where hydrogen bonds are indicated by arrows [34]. 
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2.2.3. Synthetic Second Generation of PI3K Inhibitors 
 
Previously presented compounds did not reach the clinical trials due to their toxicity and poor 
physicochemical properties, but they contributed to the examination of biological function and 
structural properties of PI3Ks, what was essential for further process of PI3K inhibitor 
development. Therefore, further improvements of already existing compounds or the syntheses of 
entirely new structures have led to the emergence of novel second generation of PI3K inhibitors. 
The development of new generation PI3K inhibitors is accomplished by combination of various 
approaches such as structure-activity relationship (SAR) analysis, in silico modeling studies based 
on three-dimensional structures of already known inhibitors bound to the catalytic site of PI3Kγ, 
classical activity-driven medicinal chemistry analogue preparation and screening of chemical 
libraries with novel enzymatic high-throughput screening assays (HTS). Some of the members of 
second generation PI3K inhibitors will be described in the following part of this chapter. 
 
PI-103 (11), discovered by Japanese company Yamanouchi, is one of the novel dual PI3K and 
mTOR inhibitor with slight better selectivity to a PI3Kα and selectivity of 6, 11, and 19 fold over 
PI3Kδ, β, γ isoform, respectively. It was reported antitumor activity in vivo without any obvious 
side effects, and its effect was attributed to its ability to target both kinases. Also it was shown that 
PI-103 (11) reduced proliferation of glioma, breast, ovarian and cervical tumour cells in xenograft 
mouse models. Unfortunately, unfavourable pharmacokinetics as well as rapid metabolism have 
been found, pointed out to necessity of further structural optimization [35], [36], [37]. 
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Figure 8. Chemical structures of the synthetic second generation inhibitors: PI-103 (11), 15e (12) and GDC-0941 (13). 
 
15e (12) is a next example of the second generation of PI3K inhibitors, belonging to the group of 
thieno[3,2-d]pyrimidine derivatives, developed by Yamanouchi Pharmaceutical. 15e (12) 
suppresses tumour cell proliferation and is pan-class I PI3K inhibitor. The poor pharmacokinetic 
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profile and the short half-life time of less than 10 minutes are reasons for limited application 
possibilities of 15e (12) in vivo [38]. 
 
Further optimization of 15e (12) resulted in a GDC-0941 (13) as a highly selective inhibitor against 
Class I PI3Ks. GDC-0941 (13) inhibited PI3Kα, β, δ and γ with IC50 of 3, 33, 3 and 75 nM, 
respectively. An anti-angiogenic effect, in vitro and in vivo, has been also reported. Replacement of 
the 3-hydroxylphenyl group with 4-indazolylgroup decreased the issue of glucuronidation and 
resulted in an acceptable oral bioavailability. GDC-0941 (13) has entered clinical phase I in 2008 
for the treatment of cancer [10], [39]. 
 
AS-252424 (14), AS-605240 (15), AS-604850 (16) are thiazolidinedione derivatives and first 
examples of selective PI3Kγ inhibitors. It was showed in mouse models in case of rheumatoid 
arthritis that these inhibitors decreased progression of joint destruction. Co-crystallization of these 
compounds with PI3Kγ helped in description and identification of their selectivity features. Based 
on these experiments, it was discovered that thiazolidinedione nitrogen makes a salt-bridge 
interaction with a side chain of Lys-833, oxygen of the 1,3-benzodioxole ring of AS-604850 (16) 
makes H-bond with the backbone amide of Val-882, while the nitrogen of the quinoxaline ring of 
AS-605240 (15) forms the link to Val-882. In case of AS-252424 (14), SAR studies showed that the 
central furan and hydroxyl group play essential role for the PI3Kγ activity [40], [41]. 
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Figure 9. Chemical structures of the synthetic second generation inhibitors: AS-252424 (14), AS-605240 (15) and AS-
604850 (16). 
 
ZSTK474 (17) is a triazine derivative, identified as PI3K inhibitor by Zenyaku Kogyo, which 
inhibited all four isoforms, with IC50 values of 16, 44, 5, 49 nM for PI3Kα, β, , and γ, respectively. 
It was reported that ZSTK474 (17) showed weaker inhibition against mTOR and DNA-PK and no 
inhibition over a panel of 139 protein kinases. Preclinical studies have shown potent anti-tumour 
activity in xenograft models in vivo at both early and advanced stages, without obvious toxicity 
[42], [43]. Due to the good results of ZSTK474 (17), it can be assumed that the effectiveness of an 
inhibitor is not associated with its absolute isoform selectivity. Since most human diseases are not 
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the result of one single pathological process it could be argued that less selective inhibitors acting 
on a wider variety of cellular processes could be more beneficial for multi-factorial diseases [44]. 
 
 
Figure 10. Chemical structures of the synthetic second generation inhibitors: ZSTK474 (17) and NVP-BEZ235 (18). 
 
NVP-BEZ235 (18) is an imidazo[4,5-c]quinoline derivative, identified as a pan-PI3K inhibitor with 
IC50 values of 4, 76, 5, and 7 nM for PI3Kα, β, , and γ, respectively. Its potent inhibition against 
mTOR was also confirmed. In addition, NVP-BEZ235 (18) also inhibited growth of a panel of 
cancer cells in vitro and showed anti-angiogenic activity. By oral administration, obvious toxicity 
was not observed. NVP-BEZ235 (18) is now in phaseI/II clinical trials for the treatment of 
advanced breast, prostate and brain cancers [45], [46]. 
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3. Research Project 
Over the last decade, the rapid increase of interest for PI3K pathway is a consequence of the intense 
research efforts of many pharmaceutical companies as well as academy. Most of these companies 
established PI3K drug development programs, which helped to arise promising molecules and some 
of them have already entered clinical trial for treatment of cancer and other diseases. On the basis of 
recent data, it does seem that isoform selectivity would be a key point for PI3K inhibitor 
development, but often impressive inhibitor selectivity in vitro, usually requires further 
optimization in vivo. Therefore, the biggest challenge for the development of an effective inhibitor 
is to find the right balance in terms of isoform selectivity and potency, to combine maximum 
efficacy in a given disease with minimal unwanted side effects. 
 
At the beginning of our project, it was not clear whether the targeting of one or all PI3K isoforms or 
maybe PI3K/mTOR will be successful in cancer therapy. Many of the PI3K inhibitors that are 
currently in clinical development inhibit all isoforms of class I PI3Ks whereas others inhibit only 
individual isoforms. For example, IC87114 (8) is PI3K specific inhibitor and has shown promising 
pharmacological activities. Since the most frequent PI3Kα gene mutation is found in human 
cancers, it is assumed that cancer therapy should be based on selective PI3Kα inhibitors. However, 
many examinations have confirmed that other isoforms are also involved in tumor genesis, 
suggesting that pan-PI3K inhibitors may enhance their therapeutic properties in curing against 
cancer. 
 
In order to answer to this oncology question, we started with intensive patent search (>400 patents, 
~100-300 pages per patent!) to identify compounds, which are under pharmaceutical development 
such as dual pan-PI3K/mTOR inhibitor PI-103 (11) (Intellectual Property (IP) of 
Piramed/Genentech/Roche, UK/USA/CH) and selective pan-PI3K inhibitor ZSTK474 (17) (IP of 
Zenyaku, Japan). We synthesized these compounds in multi-gram scale and successfully proved 
their anti-tumor activity in vitro and in vivo as well as their selectivity effect on melanoma cancer. 
Their binding mode was successfully obtained through the structure activity relationship studies and 
X-ray structure elucidation in complex with PI3Kγ. Using all information from previously 
performed research, we could rationally design novel highly active compounds. Interestingly, by 
changing a specific group of atoms or even a single atom by the known inhibitors we could have an 
affect in increase of both selectivity as well as potency. 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 24
 
 
4. Discussion and Results 
4.1. ZSTK474 Derivatization 
Until now, the emphasis is placed on targeting of specific isoforms within the Class I in order to 
provide selective inhibitors, which contribute to reduction of toxicity without loss of efficiency. 
Stimulated by the same fact, we tried to increase isoform selectivity and to improve 
physicochemical properties from already known pan-PI3K inhibitor ZSTK474 (17) identified by 
Japanese pharmaceutical company Zenyaku Kogyo. We tried to increase the selectivity against 
PI3K by using all information obtained from structure-activity relationship (SAR) studies, X-ray 
crystal structure of ZSTK474 (17) in complex with PI3Kγ and PI3K and modeling studies. 
Compared to other novel PI3K inhibitors, ZSTK474 (17) displayed significantly less activity 
against the mTOR, DNA-PK and no inhibition against panel of 139 protein kinases [39], [42]. 
Therefore, selective targeting of PI3K family and unpublished SAR studies of ZSTK474 (17) from 
the competitor, prompted us to improve its selectivity profile activity within the class I PI3K family. 
 
4.1.1. Triazine Chemistry 
 
 
 
Scheme 3. Reagents and conditions: a) cyanuric chloride (1.0 eq.), morpholine (4.5 eq.), DMF, 0 °C, 20 minutes, 56 %; 
b) amine (1.1 eq.), DMF, NaH (60% in mineral oil, 1.5 eq.) added at 0 °C, 30 minutes at room temperature, then reflux 
at 153 ° C for 3.5 - 5.5 hours, 13 – 77 %. 
 
Compounds (28-33) (Table 1) are produced as presented in (Scheme 3). Cyanuric chloride (19) was 
substituted by two morpholine units in DMF, at 0 °C for 20 minutes, giving the intermediate (20). 
Further replacement of the third chlorine was done by nucleophilic substitution with several 
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heterocyclic aromatic amines, in presence of NaH as a base and DMF as a solvent, refluxing at 153 
°C for 3.5 - 5.5 hours. 
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Scheme 4. Reagents and conditions: a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 minutes, 28 %; b) K2CO3, (1.44 eq.), 
heterocyclic aromatic compound (1.4 eq.), DMF, 30 minutes at -5 °C, 3 - 4 hours at room temperature, 60 – 80 %; c) 
morpholine (1.2 eq.), K2CO3 (3.2 eq.), DMF, room temperature, 45 minutes - 2 hours., 60 - 95 %. 
 
Compounds (34-50) (Table 2, 3, 5, 6 and 8) have been synthesized following the procedure reported 
in Schemes 4 and 5. Cyanuric chloride (19) was substituted by morpholine in methylene chloride at 
-50 °C for 20 minutes to give intermediate (22). Replacement of the second chlorine center with 2-
difluoromethyl-1H-benzoimidazole or a heterocyclic aromatic amine in presence of K2CO3 in 
DMF, at -5 °C for 30 minutes and further stirring at room temperature for 3 - 4 hours led to 
intermediates (23) (Scheme 4) and (25) (Scheme 5). The final step gave products (24) (Scheme 4) 
and (26) (Scheme 5) by process of amination in presence of K2CO3 and DMF at room temperature 
for 45 minutes, or products with the general structure (27) (Scheme 5) by Suzuki coupling of 
intermediate (25) with appropriate boronic acid pinacol esters, dichloro 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex as a catalyst in 
1,2-dimethoxyethane:2M Na2CO3 (3:1) as a solvent and stirring overnight at 90 °C. 
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Scheme 5. Reagents and conditions: a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 minutes, 28 %; b) K2CO3, (1.44 eq.), 
2-difluoromethyl-1H-benzoimidazole (1.4 eq.), DMF, 30 minutes at -5 °C, 3 - 4 hours at room temperature, 60 – 80 %; 
c) amine (1.2 eq.), K2CO3 (3.2 eq.), DMF, room temperature, 45 minutes - 2 hours., 60 - 95 %; d) boronic acid pinacol 
ester (4.0 eq.), 1,2-dimethoxyethane:2M Na2CO3 (3:1), dichloro 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 - 20 hours. 
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4.1.2. Fragment Validation Step as an Effective Method in Process of Creating 
Novel and Active ZTSK474 Derivatives 
 
Through our fragment validation step (Figure 11) we examined which structural fragments of the 
known PI3K inhibitor ZSTK474 (NCB38) are significant for biological activity and which could 
serve for further chemical optimization. For this purpose, several derivatives of ZSTK474 (NCB38) 
were synthesized (Table 1, Table 2 and Table 3), and the nature of their interactions with the target 
protein was analyzed by different cellular assays, X-ray and in silico experiments. We determined 
the crystal structure of PI3K in complex with ZSTK474 (NCB38) (Figure 12), which has shown 
that the key hydrogen bonds were made through the interaction of morpholine oxygen with the 
backbone amide of the hinge Val-882 and fluorine of difluoromethyl group with Lys-833. The 
contact list with exact description of amino acids responsible for the hydrogen bond formations and 
for hydrophobic interactions is given in the table on a page 100. 
 
 
 
Figure 11. In the fragment validation step we examined, which structural fragments of the known PI3K inhibitor 
ZSTK474 (NCB38) are significant for biological activity, and which could serve for further chemical optimization. For 
this purpose, we modified all possible positions around the molecular scaffold and synthesized several analogues of the 
ZSTK474. Activity and the binding mode of those ZSTK474 analogues were further analyzed by different cellular 
assays, X-ray and in silico experiments. 
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Insertion of trifluoromethyl group instead of a difluoromethyl group leads to reduction of activity, 
while the absence of difluoromethyl group leads to poor in cell inhibition that can be explained by 
the lack of hydrogen bond with Lys-833 where the fluorine atom of the difluormethyl group serves 
as an H-bond acceptor. Substitution of one morpholine with various piperazine groups did not 
drastically affect the biological activity, what inspired us to continue to modify one morpholine unit 
in order to create novel, active and more selective PI3K inhibitors. 
 
 
Figure 12. A) Represented is a surface diagram of X-ray elucidated ZSTK474-PI3Kγ complex zoomed into the ATP 
binding site. Amino acids residues and the ligand are represented in stick form, coloured according to the element (C 
atoms in grey, N atoms in blue, O atoms in red); B) Extracted amino acids mediating PI3K/ZSTK474 interactions 
within the ATP-binding site; the electron density map of the compounds is presented in magenta mesh. Only hydrogen 
bonds that we are confident with are shown as black dashed lines. 
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Table 1. Inhibitor activitya  
N
N
N
N
N R1
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R1 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCA173) 28 
 
65 161.65 ± 7.46 92.88 ± 2.95 87.95 ± 2.80 
(NCA77) 29 
N N
 
69 77.09 ± 2.02 69.65 ± 1.64 55.85 ± 3.90 
(NCA181) 30 
N N
 
89 129.38 ± 2.00 91.11 ± 2.58 92.08 ± 6.95 
(NCA152) 31 
N
 
86 127.52 ± 9.28 89.69 ± 4.86 81.07 ± 4.80 
(NCB82) 32 
 
92 85.79 ± 2.40 102.32 ± 0.54 80.18 ± 10.39 
(NCA111) 33 N N
CF3
 
25 63.69 ± 9.14 63.84 ± 6.37 69.99 ± 13.34 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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Table 2. Inhibitor activitya  
N
N
N
N
N R2
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R2 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB53) 34 N N
CH3
 
53 16.02 ± 1.15 65.58 ± 1.32 91.59 ± 0.46 
(NCB94) 35 N N
Cl
 
28 33.84 ± 1.75 61.62 ± 5.42 98.16 ± 10.25 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on 
melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured by 
Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red -
good activity, orange - very good activity. 
 
 
High inhibitor activity of compounds (34) and (35) (Table 2) could be explained by the concept of 
bioisosterism. Bioisosterism represents one approach used by the medicinal chemist for the rational 
modification of compounds into more effective agents. Reasons to use bioisosterism are to design 
new drugs by including improvement of the pharmacological activity, determination of the 
selectivity for an enzymatic isoform subtype, optimization of the pharmacokinetics and toxicity 
effects. This concept is very often used by pharmaceutical industry to discover new therapeutically 
innovative and commercial attractive analogs. Bioisosteres may be atoms and molecules that 
possess similar molecular shapes, volumes, similar distribution of electrons, physical properties and 
have a similar type of biological activity [47] For example, the substitution of hydrogen by fluorine 
is one of the more commonly bioisosteric replacements. Steric parameters of these atoms are 
similar; their van der Waal’s radii are 1.2 (for hydrogen) and 1.35 Å (for fluorine). Their 
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pharmacological differences can be attributed to the influence of the electron-withdrawing effect 
that the fluorine substitution causes on interaction with either a biological receptor or enzyme. 
Bioisosteric replacement of the methyl group in compound (34) with the chlorine atom led to the 
compound (35). The chlorine atom is often viewed to be isosteric and isolipophilic with the methyl 
group. Exchange of the methyl group with the chlorine atom can increase the metabolic stability of 
the relevant compound [48]. 
 
Table 3. Inhibitor activitya  
N
N
N
N
R3 N
O
NF
F  
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R3 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB55) 36 
 
45 21.69 ± 0.53 106.52 ± 2.90 70.53 ± 3.63 
(NCB56) 37 
 
42 9.07 ± 1.49 54.20 ± 3.91 68.85 ± 1.08 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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4.1.3. Synthesis of Novel, Active and Selective ZSTK474 Derivatives 
 
Structural studies showed that one of the determinants, which influence kinase inhibitor selectivity, 
termed as “gatekeeper” residue is placed in hydrophobic pocket of ATP binding site. Smaller 
gatekeepers such as threonine allow bulky substituents to enter deeper into the hydrophobic pocket 
in contrast to the larger gatekeeper residues such as methionine or phenylalanine which prevent 
access to this pocket. An example that exploits this kind of selectivity filter is Gleevec a known 
drug used to treat chronic myelogenous leukemia by utilizing a threonine gatekeeper in the Abl 
tyrosine kinase domain [49]. The analyses have shown that mutation of threonin gatekeeper residue 
into the larger amino acid is one of the most common mechanisms of resistance to Gleevec. 
 
In recant docking studies and molecular modeling experiments by utilizing the available crystal 
structures of PI3Kγ and PI3Kα, Zvelebil and colleagues revealed that one of the differences 
between p110α and other PI3K isoforms of class I is absence of Asp-Lys as a gatekeeper pair only 
in p110 (Asp950-Lys807 in p110γ, Asp897-Lys755 in p110 and Asp923-Lys782 in p110β) 
(Table 4). Appropriate residues in p110α are Ser-919 and Ala-775 respectively (Figure 13). In 
contrast to Asp-Lys pair, Ala-Ser pair can not create intramolecular hydrogen bond because of their 
large enough mutual distance, enabling affordable access to hydrophobic region of ATP pocket and 
more convincing binding mode [50]. Taking into account their smaller size relating to Asp-Lys pair, 
it is clear that Ser-Ala gatekeeper residues may allow easier and fuller access to hydrophobic ATP 
pocket that could lead to a simultaneous improvement in selectivity and potency of appropriate 
inhibitors. 
 
 
Table 4. Residues that have been identified by close structural inspection of each isoform to be part or near the ATP 
binding site. The residues framed in red colour are those that differ between the class I PI3K isoforms [50]. 
 
In aim to achieve that effect, we substituted one of two morpholine units of ZSTK474 (38) with 
bulky heterocyclic analogs with the strategy that such substitution will fill a free cavity within the 
hydrophobic pocket II of the ATP binding pocket in PI3K isoforme (Figure 14). 
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Figure 13. The ATP binding site from the X-ray structure (blue ribbon) imposed on the modelled structure (gray 
backbone) of p110. The gatekeeper residues described previously are presented as sticks and coloured blue in the X-
ray structure and red in the model [50]. 
Docking studies assumed that this substitution would lead to greater specificity amongst the 
isoforms. Interestingly, comparing to ZSTK474 (38), introduction of diverse morpholine 
substituents (Scheme 5, Table 5) by amination process as: dimethyl morpholine NCB136 (39), 
homomorpholine NCB137 (40) and bridged morpholine NCB138 (41) led those derivatives to 
better inhibition in cellular assay, greater selectivity to mTOR and similar inhibition in vitro against 
PI3Kα. In case of 1-methylhomopiperazine NCB87 (42) replacement, slight less activity was 
obtained in vitro experiments and in cell inhibition (pPKB/PKB), but significant decreasing of 
selectivity towards mTOR (Figure 15). 
 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 34
 
 
 
Figure 14. ZSTK474 morpholine unit (coloured in blue) is located at the entrance of the ATP binding pocket 
(hydrophobic pocket II) and was exchanged with bulky morpholine or piperazine analogs with the aim to fill a free 
cavity within hydrophobic pocket II in PI3K isoforme. 
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Table 5. Inhibitor activitya  
N
N
N
N
R4 N
O
NF
F  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R4 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB38) 38  13 12.83 ± 7.03 19.46 ± 1.53 20.67 ± 1.39 
(NCB136) 39 
N
O
 
16 8.31 ± 3.56 30.09 ± 1.21 5.60 ± 1.49 
(NCB137) 40 
 
22 3.86 ± 1.17 21.14 ± 1.82 9.77 ± 1.79 
(NCB138) 41 
 
18 2.21 ± 4.81 34.44 ± 4.39 10.75 ± 0.71 
(NCB87) 42 
 
34 24.74 ± 1.88 78.63 ± 5.58 86.52 ± 7.45 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured 
by Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red - 
good activity, orange - very good activity. 
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Optimized ZSTK474 Derivatives, Part I 
0
20
40
60
80
100
NCB38 NCB136 NCB137 NCB138 NCB87
Inhibitor
%
 R
em
ai
ni
ng
 a
ct
iv
ity
pPKB/PKB_1 µM pS6_1 µM TSC2-/-MEFs pS6_1 µM 200 nM PI3Ka
 
Figure 15. Presented is cellular activity (pPKB/PKB and pS6 on A2058 and pS6 on TSC2-/-MEFs) at 1 μM and in 
vitro activity against PI3K at 200 nM; the lower the bar chart the better is the activity of the relevant compound. 
 
 
The next step was the insertion of aromatic substituents by Suzuki coupling instead of morpholine 
(Scheme 5, Table 6). In the same time we also applied fluorine strategy in our project. As already 
known, introducing of fluorine in inhibitors can lead to an increase of metabolic stability, 
lipophilicity, binding affinity in protein-ligand complexes and regulation of physicochemical 
properties [51]. However, replacement of morpholine by fluorinated aromatic reagents 3,5-
bis(trifluoromethyl)-phenylboronic acid NCB48 (44) did not lead to expected results, which can be 
explained by rigid and too bulky aromatic system and its inability to fit into the hydrophobic 
pocket. Better results in vitro and in cell inhibition are obtained in case of 2,4-
difluorophenylboronic acid pinacol ester NCB51 (43) and 4-(4-morpholinomethyl)-phenylboronic 
acid pinacol ester NCB49 (45) replacement, compared to NCB48 (44) (Figure 16). 
 
 
 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 37
 
Table 6. Inhibitor activitya 
N
N
N
N
R6 N
O
NF
F  
A2058 cell inhibition TSC2-/-MEFs cell inhibition
Compound R6 In vitro PI3Kα200 nM pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB38) 38  13 12.83 ± 7.03 19.46 ± 1.53 20.67 ± 1.39 
(NCB51) 43 
 
31 56.42 ± 3.14 104.47 ± 3.78 98.78 ± 1.46 
(NCB48) 44 
 
115 88.97 ± 13.09 112.65 ± 1.71 110.59 ± 2.10 
(NCB49) 45 
 
41 64.73 ± 7.84 96.27 ± 6.59 72.26 ± 2.24 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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Optimized ZSTK474 Derivatives, Part II
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Figure 16. Presented is cellular activity (pPKB/PKB and pS6 on A2058 and pS6 on TSC2-/-MEFs) at 1 μM and in 
vitro activity against PI3K at 200 nM; the lower the bar chart the better is the activity of the relevant compound. 
 
 
The further step was the improvement of physicochemical properties of ZSTK474 (38) by applying 
a sulfone strategy (Scheme 5). Insertion of sulfone group causes reduction of lipophilicity because 
of its high electron withdrawing and basicity-reduced effect [52]. We observed how different 
fragments containing the sulfone group inserted instead of morpholine modulate the biological 
activity and selectivity of ZSTK474 (38) derivatives to PI3K and mTOR (Table 7 and Table 8). 
 
Comparing to ZSTK474 (38), introducing of more basic piperidine NCB37 (46) instead of 
morpholine, caused a significant decrease in activity towards mTOR in A2058 cell line. 
Interestingly, inhibition of pS6 phosphorilation in TSC2-/-MEFs cell line was improved as well as 
inhibition of pPKB/PKB phosphorilation in A2058 (Table 8, Figure 18). Reduction in activity was 
noticed in vitro experiments against PI3K. Replacement with more acidic and more soluble 
thiomorpholine 1,1-dioxide NCB91 (47) led to considerable reduction in biological activity both in 
vitro and in cell inhibition. The next thing what we explored is influence of N-methylpiperazine 
NCB36 (48) and sulphonyl containing piperazine NCB60 (49), NCB57 (50) on activity and 
selectivity against PI3K and mTOR. Increasing of activity against PI3K, but significant diminishing 
of selectivity to mTOR in TSC2-/-MEFs cell line was obtained by insertion of N-methylpiperazine 
NCB36 (48). Crystal structure of PI3Kγ in complex with NCB36 (48) (Figure 17) explained 
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increment of activity by the presence of additional hydrogen bond of N21 with Asp-964. 
Interestingly, replacement with more acidic and more soluble 1-(methylsulfonyl)piperazine NCB60 
(49) led to even better activity in cell experiments comparing to ZSTK474 (38). When 1-
(ethanesulfonyl)piperazine NCB57 (50) (with similar acidity to 49) was introduced, biological 
activity against PI3K was slight decreased, while activity to mTOR became notable reduced. 
 
 
Table 7. Physicochemical propertiesa 
No  pKa LogP LogD Log(S) 
1.  11.1
b 0.93 ± 0.24 -2.1 ± 1.0 -0.17 
2.  8.5
b -1.08 ± 0.27 -3.0 ± 1.0 1.48 
3.  5.4
b -1.45 ± 0.47 -1.6 ± 1.0 -0.14 
4.  
c9.65 ± 0.25 
d4.35 ± 0.30 
-0.18 ± 0.32 -2.7 ± 1.0 0.84 
5. 
 
c6.38 ± 0.25 
d-8.68 ± 0.20 
-0.67 ± 0.48 -0.8 ± 1.0 -0.67 
6. Nc NdH S
O
O
 
c6.38 ± 0.25 
d-8.69 ± 0.20 
-0.14 ± 0.48 -0.2 ± 1.0 -1.04 
aPhysicochemical properties were calculated using a commercial database [53]. pKa = Amine 
basicity; LogP = Intrinsic lipophilicity; LogD = Logarithmic n-octanol/water distribution 
coefficient at pH = 7; Log(S) = Logarithm of Intrinsic solubility of the neutral base. 
bExperimental pKa values [53].cpKa1; dpKa2. 
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Figure 17. A) Represented is a surface diagram of X-ray elucidated NCB36-PI3Kγ complex zoomed into the ATP 
binding site. Amino acids residues and the ligand are represented in stick form, coloured according to the element (C 
atoms in grey, N atoms in blue, O atoms in red); B) Extracted amino acids mediating PI3K/ZSTK474 interactions 
within the ATP-binding site; the electron density map of the compounds is presented in magenta mesh. Only hydrogen 
bonds that we are confident with are shown as black dashed lines. 
 
According to our molecular modelling experiments, we concluded that oxygen atom of sulfonyl 
group has the potential to form an additional hydrogen bond with the target protein making this 
compound more potent. Additionally, due to the polarity of the sulfonyl group compound NCB60 
(49) has better water solubility comparing to ZSTK474 (38). This could partially explain better 
inhibitor activity of compound NCB60 (49). 
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Table 8. Inhibitor activitya 
N
N
N
N
R5 N
O
NF
F  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R5 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB38) 38  13 12.83 ± 7.03 19.46 ± 1.53 20.67 ± 1.39 
(NCB37) 46  39 9.36 ± 0.35 57.48 ± 2.75 7.13 ± 0.34 
(NCB91) 47  34 49.03 ± 11.85 98.88 ± 10.16 57.86 ± 0.40 
(NCB36) 48  33 0.17 ± 2.27 23.19 ± 1.00 93.26 ± 0.97 
(NCB60) 49 
 
17 -2.03 ± 1.80 12.79 ± 0.31 12.14 ± 0.11 
(NCB57) 50 
 
35 18.27 ± 1.13 82.15 ± 9.79 73.72 ± 5.61 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on 
melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured by 
Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red -
good activity, orange - very good activity. 
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Figure 18. Optimization of ZSTK474 by applying sulfone strategy. Presented is cellular activity (pPKB/PKB and pS6 
on A2058 and pS6 on TSC2-/-MEFs) at 1 μM and in vitro activity against PI3K at 200 nM; the lower the bar chart the 
better is the activity of the relevant compound. 
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4.2. Structure-Based Design of Irreversible PI3K Inhibitors 
Structure-based drug design relies on knowledge of the three dimensional structure of the biological 
target obtained through methods such as X-ray crystallography or NMR spectroscopy. If an 
experimental structure of a target is not available, it may be possible to create a homology model of 
the target based on the experimental structure of a related protein. Based on information obtained 
from the crystal structure of PI3K and PI3K in complex with ZSTK474 (38) we designed the 
inhibitors, which could improve their activity and selectivity through covalent interaction with 
enzyme or protein receptor. Known irreversible inhibitors, usually possess electrophilic functional 
groups such as α, β-unsaturated carbonyls or halomethyl carbonyls that covalently modify 
nucleophilic amino acids such as cysteine, serine, threonine or tyrosine. However, due to the higher 
probability of toxicity as a result of covalent binding, there has been a tendency to avoid covalent 
drugs. In contrast there are many effective irreversible acting drugs on the market such as aspirin, 
penicillin, entire class of β-lactam antibiotics and many others [54]. Advances in chemical biology 
and bioinformatics data analysis methods has contributed more easily identifying and predicting a 
level of toxicity of a covalent modification, allowing further progress in the development of 
covalent inhibitors. 
 
4.2.1. Benefits of Covalent Binding Mechanism 
 
There are several considerable advantages by targeting appropriate proteins or enzymes with small 
molecular weight covalent inhibitors. 
 
 Increased selectivity: Due to their ability to form covalent bonds with suitable amino acids 
residues that are unique to disease-causing proteins, covalent drugs contribute to enhanced 
selectivity, which leads to better efficacy and reducing of side-effects. 
 
 Prolonged duration of action: In account of such unique mode of complete binding to a 
protein drug target, covalent drugs effectively ‘silence’ their targets, which remain silenced until 
their novel cellular production. Thus, covalent drugs lead to a prolonged duration of action, in 
contrast to most current drugs which need to maintain high exposure, while the protein-drug 
interaction is temporary. The benefits of this include the potential for better efficacy, less frequent 
dosing and less overall drug exposure that should improve safety. 
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 Mutational resistance: Often mutation of disease-causing proteins leads to changes of 
proteins binding site in their shape and size, what usually prevent or decrease effective binding of 
conventional drugs. However, because covalent drugs only must attack the protein once in order to 
form a strong bond, they will not easily separate from a mutated protein and can retain efficacy. 
Therefore covalent drugs are particularly well-suited to the treatment of cancers. 
 
4.2.2. Published Irreversible Kinase Inhibitors 
 
This chapter will present a short overview about already published irreversible kinase inhibitors in 
last several years. Focus will be directed towards diverse protein kinases as most frequent targeted 
proteins by irreversible molecules. Additionally, natural PI3K inhibitor wortmannin (1) as 
irreversible PI3K inhibitor will be briefly described. 
 
HKI-272 (51) is HER-2 irreversible inhibitor and was discovered by Wyeth five years ago. HER-2 
belongs to the ErbB family of receptor tyrosine kinases, which has been involved in a development 
of various cancer diseases. Overexpression of HER-2 is found in ~ 30% of breast cancer patients, 
therefore blocking of its function by small molecule kinase inhibitors may lead to inhibition of 
growth of HER-2 positive tumors. HKI-272 (51) reduces HER-2 autophosphorylation in cells and 
affects the inactivation of downstream signal transduction events. In vivo, this inhibitor is also 
active in HER-2 depended tumor xenograft models by orally administration. HKI-272 (51) contains 
a Michael acceptor functional group, which covalently reacts with sulfhydryl group of Cysteine-805 
located within the catalytic core of HER-2. In xenograft studies, HKI-272 (51) was well tolerated 
without obvious toxicity [55]. 
 
 
Figure 19. Chemical structures of the irreversible kinase inhibitors: HKI-272 (51) and Canertinib (52). 
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Canertinib (CI-1033) (52) is an irreversible nonselective EGFR inhibitor with an IC50 value at low 
nanomolar range. It was found that Canertinib (52) is active against human breast carcinomas both 
in vitro and in vivo tumor xenograft models. In clinical phase II Canertinib (52) was tested against 
metastatic nonsmall cell lung cancer and metastatic breast cancers. The most common side effect 
associated with Canertinib (52) were diarrhea, skin rush, nausea and stomatitis [56]. 
 
Bruton’s tyrosine kinase (Btk) is a member of Tec family kinases and is a key component in the B-
cell receptor signal pathway (BCR). Pyrazolo-pyrimidine containing Btk inhibitor (53) has an IC50 
value in the subnanomolar range and it showed dose-dependent efficacy in a mouse arthritis model 
[57]. 
 
Compound (54) is irreversible kinase inhibitor of Wyeth-Ayerst with IC50 of 38.5 nM against EGFR 
receptor tyrosin kinase. It was developed with the aim to treat nonsmall cell lung cancer (NSCLC), 
colorectal neoplasia and other EGFR depended solid tumours. The reactive acryl group of 
compound (54) is able to interact through the Michael addition with the cysteine or serine residues 
within the binding pocket of EGFR paralogous [58]. 
 
 
Figure 20. Chemical structures of the irreversible kinase inhibitors: compound (53) and (54). 
 
FIIN-1 (56) is a first irreversible inhibitor of FGFRs with nanomolar in vitro IC50 values against 
FGFR1 isoforms. FIIN-1 (56) was created on the basis of structural information of compound 
PD173074 (55) bound to tyrosine kinase receptor FGFR1 (Figure 21). Insertion of acrylamide 
moiety led to formation of a covalent bond with Cysteine-486, placed in the P loop within the active 
site of the protein. FIIN-1 (56) showed high degree of selectivity against the panel of 402 kinases. 
The IC50 values were determined to be 9, 6, 12, and 189 nM against FGFR1, FGFR2, FGFR3, and 
FGFR4, respectively. Binding and activity assays suggest that FIIN-1 (56) is a selective FGFR 
inhibitor [59]. 
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Figure 21. Chemical structures of PD173074 (55) and irreversible kinase inhibitor FIIN-1 (56). 
 
Wortmannin (1) is natural and only known irreversible PI3K inhibitor. As previously described, 
wortmannin (1) covalently reacts with Lys-802 residue of PI3Kα. Wymann and co-workers 
discovered that ε-amino group of Lys-802 attacks C-20 of wortmannin (1) which results in furan 
ring opening to form an enamine (Scheme 2). It is important to note that wortmannin (1) is a 
bimodal inhibitor, what means that inhibition of PI3K is established through both non-covalent 
interactions as well as covalent modification of lysine that leads to irreversible adduct [60]. 
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4.2.3. Michael Addition of Amine and Thiol Nucleophiles to the Acryl 
Containing Probe VCA20 in Water 
 
The extensive chemistry of protein-reactive wortmannin (1) was a forceful inspiration for the design 
of synthetic irreversible PI3K inhibitors. The furan ring of natural product is double activated with 
two acrylic Michael systems. In order to create effective synthetic irreversible PI3K inhibitor, we 
inserted firstly the acrylamide group as an electrophilic group for the covalent modification of PI3K 
(Scheme 6). 
 
 
Scheme 6. Double Michael system (red) makes wortmannin (1) attractive for attack of Lys-802 on C-20 position (blue); 
decision to use acrylamide moiety as a reactive group for creation of irreversible PI3K inhibitor. 
 
It was suggested that free lysine residues from the proteins could react with the electrophilic acrylic 
group in the similar manner as the active Lys-802 with wortmannin (1) through the Michael 
addition. That assumption was proven during the master work studies of Cmiljanovic V. (data 
unpublished). In vitro proof was based on the use of butylamine as imitation of lysine site chain that 
was added to the acryl containing chemical probe VCA20 under physiological conditions. After ~ 
50 hours of reaction at 37 °C in phosphate buffer (PBS buffer, pH 7.4), desired product was 
obtained in quantitive yield as the only product. After encouraging results, several different amines 
and thiol nucleophiles were tested with VCA20 under same conditions. In almost all cases a 
decrease of NMR chemical shifts for acryl amid protons was observed. 
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Scheme 7. Investigated nucleophiles in Michael addition to VCA20 in H2O. Conditions: nucleophile (2.0 eq.), PBS 
buffer (pH 7.4), ~ 50 hours, 37 °C; A) VCA20 (1.0 eq.), Ac-Cys-OH (3.3 eq.), PBS buffer (pH 9.3), 150 h, 38 - 40 °C, 
70%; B) VCA20 (1.0 eq.), lysine HCl (10 eq.), PBS buffer (pH 9.3), ~ 166 hours, 38 - 40 °C, 42% (Cmiljanovic V. 
master work-unpablished). 
 
The results of reactions presented in (Scheme 7) indicated the possibility for Michael addition of 
both lysine as well as cysteine to the acryl containing chemical probes. Therefore, the further step 
was focused on reaction of VCA20 with lysine and cysteine as nucleophile reagents. Addition of 
those amino acids to VCA20 was followed by kinetic measurements. Due to the very slow lysine 
and cysteine addition to VCA20 in water by pH 7.4, the measurements were carried on pH ~ 9. The 
reaction A in (Scheme 7) with Ac-Cys-OH gave better yield (70%, after 150 hours of reaction time) 
in contrast to reaction B with lysine (42%, after 166 hours of reaction time). Motivated by these 
results, we attached the acrylamide group to PI3K inhibitor ZSTK474 (38) in order to covalently 
target appropriate lysine moiety in PI3Kγ, located at the entrance of hydrophobic region of the ATP 
pocket. 
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4.2.4. Selectivity Filter Approach for Successful Design of Irreversible Inhibitors 
 
In order to create more selective and potent PI3K inhibitors, we started from ZSTK474 (38) as a 
selective inhibitor for class I PI3K family. Here, it will be described a rational design of irreversible 
PI3K inhibitors. 
 
On the basis of X-ray structural studies of PI3Kγ in complex with ZSTK474 (38) as well as docking 
studies of the same inhibitor to the other class I PI3K isoforms (Figure 22), we identified amino 
acids at the entrance of the ATP-binding pocket, available only by PI3Kγ and not by other isoforms. 
Additionally, we identified amino acids available only by PI3K and not by other PI3K isoforms. 
Selective targeting of these amino acids could lead to the first isoform-selective PI3Kγ and PI3K 
inhibitors. By PI3Kγ isoform we identified Lys-890 as a “selectivity filter” residue. According to 
the X-ray crystal structure of ZSTK474 (38) in complex with PI3Kγ, Lys-890 makes hydrophobic 
contacts with the morpholine group of the ligand at the entrance of the hydrophobic pocket II (see 
page 100). By using a sequence alignment analysis of the PI3K isoforms we observed that other 
PI3K isoforms do not contain an appropriate lysine residue at the entrance to the hydrophobic 
pocket II. It was motivating us to design novel compounds for selective targeting of PI3Kγ. 
Additionally, we identified Cys-862 in PI3Kα, respectively Lys-841 in PI3K as selectivity filter 
residues (Figure 22). According to the modeling studies by PI3K and X-ray crystal structure by 
PI3K these residues are not closely located to the ligand ZSTK474 (38), so by there targeting a 
linker strategy has been applied. 
 
By using this structural information, we design a small library of possible irreversible PI3K 
inhibitors by insertion of different chemical electrophilic groups at the morpholine moiety of 
ZSTK474 (38) that could covalently bind to nucleophilic residues such as Lys-890 by PI3Kγ, Cys-
862 by PI3K or Lys-841 by PI3K. 
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Figure 22. A) Represented is a surface diagram of X-ray elucidated ZSTK474-PI3Kγ complex zoomed into the ATP 
binding site; B) Surface diagram of ZSTK-PI3Kα complex, where ZSTK474 has been manually docked to the X-ray 
crystal structure of PI3K; C) Surface diagram of X-ray elucidated ZSTK474-PI3Kδ complex. Identified nucleophilic 
amino acid residues as well as ligand ZSTK474 are represented in a stick form, colored according to the element (C 
atoms in yellow, N atoms in blue, O atoms in red, and F atoms in green). In figures A’, B’ and C’ represented is a 
ribbon diagram of appropriate ligand-PI3K complex. 
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4.2.5. Chemistry and Biology of Irreversible ZSTK474 Derivatives 
 
During our SAR studies we discovered that the exchange of one morpholine ring with appropriate 
piperidine and piperazine derivatives in ZSTK474 (38) does not have a considerable effect on 
reduction of inhibitor activity. Therefore we replaced morpholine ring with electrophilic group 
containing piperazine derivatives with the aim to create isoform selective irreversible PI3K 
inhibitors. 
 
 
 
 
Scheme 8. Chemical modifications of ZSTK474 through the replacement of morpholine with piperazine and piperazine 
derivatives bearing an electrophilic reactive group to yield possible irreversible ZST474 analogs. 
 
As previously described, during my PhD work we elucidated the X-ray crystal structure of 
ZSTK474 in complex with PI3Kγ. To target the identified selectivity filter amino acid Lys-890 by 
PI3Kγ we performed the chemistry described in (Scheme 9). 
 
Cyanuric chloride (19) was substituted by morpholine in methylene chloride, at -50 °C for 20 
minutes to give intermediate (22). Replacement of second chlorine center with 2-difluoromethyl-
1H-benzoimidazole in presence of K2CO3 in DMF, at -5 °C for 30 minutes and further stirring at 
room temperature for 4 hours led to the intermediate (25). The next step gave product (57) by 
amination with 1-boc-piperazine in presence of K2CO3 and DMF as a solvent at room temperature 
for 45 minutes. Further, compound (58) was obtained by Boc deprotection in HCl (dioxane 
solution), stirring at room temperature for 1.5 hours in methylene chloride as a solvent. Final 
product (59) was obtained by amidation with appropriate anhydride reagent, by stirring at room 
temperature for 1-2 hours in methylene chloride and in presence of N,N-diisopropylethylamine as a 
base. 
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Scheme 9. Reagents and conditions: a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 minutes, 28 %; b) K2CO3, (1.44 eq.), 
2-difluoromethyl-1H-benzoimidazole (1.4 eq.), DMF, 30 minutes at -5 °C, 4 hours at room temperature, 65 %; c) 1-
boc-piperazine (1.2 eq.), K2CO3 (3.2 eq.), DMF, 1 hour at room temperature, 95 %; d) compound (57) (260 mol, 1.0 
eq.), HCl in dioxane (~2 ml), CH2Cl2, 1.5 hours at room temperature, 100 %; e) N,N-diisopropylethylamine (1.1 eq.), 
electrophilic group (1.0 eq.), CH2Cl2, 1 - 2 hours at room temperature, 37 – 88 %. 
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Table 9. Inhibitor activitya  
N
N
N
N
NN
N
O
N
F
FR
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R In vitro PI3Kα200nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB141) 80 
 
8.1 45.26 ± 2.98 75.84 ± 0.86 98.78 ± 0.73 
(NCB144) 81 
 
7.4 8.43 ± 0.66 25.5 ± 1.06 37.40 ± 1.55 
(NCB145) 82 
 
3.4 12.34 ± 1.93 24.48 ± 1.66 94.32 ± 2.25 
(NCB147) 83 
 
8.5 17.96 ± 2.13 32.53 ± 0.30 67.06 ± 4.75 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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Scheme 10. Reagents and conditions: a) tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (GSA79) (0.6 eq.), 
potassium carbonate (3.2 eq.), DMF, room temperature, 3 hours, 95%; b) trifluoroacetic acid/methylene chloride 1:2, 
room temperature, 2 hours, 80%; c) acrylic anhydride (1.0 eq.), DIPEA (1.1 eq.), CH2Cl2, room temperature, 1.5 hours, 
68 %. 
 
Considering the good biological activity of compound GSA44 (63), we decided to synthesize an 
acrylamid containing spiropiperazine derivative (Scheme 10 and Table 10). According to (Scheme 
11) produced mono N-boc protected spiropiperazine GSA79 (73) was coupled onto compound (25). 
Then the Boc group of azetidine GSA93 (60) was cleaved by treatment with trifluoroacetic acid to 
give the free amine GSA95 (61). Final product GSA100 (62) was obtained by amidation with 
acrylic anhydride, by stirring at room temperature for 1.5 hours in methylene chloride and N,N-
diisopropylethylamine as a base. 
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Table 10. Inhibitor activitya  
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R1 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(GSA100) 62 
 
22 38.25 ± 3.46 61.57 ± 0.38 131.22 ± 17.94
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
 
 
The synthesis of N-tosyl-2-oxa-6-azaspiro[3.3]heptane GSA12/43 (66) was investigated by the 
group of Prof. Carreira from ETH Zurich. Then the oxetan moiety was opened with hydrobromic 
acid to give bromoalcohol GSA67 (67) in quantitative yield. This bromoalcohol GSA67 (67) was 
transformed via an Apple reaction into di-brominated compound GSA68 (68), which was further 
reacted with benzylamine (69) to provide 2-benzyl-6-tosyl-2,6-diazaspiro[3.3]heptane GSA71 (70). 
Hydrogenolytic cleavage of the N-benzyl group and subsequent treatment with Boc2O gave N-Boc 
protected azetidine GSA78 (71). The last step is again the tosylate deprotection, to give tert-butyl 
2,6-diazaspiro[3.3]heptane-2-carboxylate GSA79 (73). 
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Scheme 11. Reagents and conditions: a) 3-bromo-2,2-bis(bromomethyl)propan-1-ol 64 (1.0 eq.), p-tosylamide (65) (1.2 
eq.), potassium hydroxide (3.2 eq.), ethanol, 90 °C, 94 hours, 56-63 %; b) HBr (33 % in AcOH, 1.2 eq.), diethyl ether, 0 
°C → 25 °C, 45 minutes, 98 %; c) PPh3 (1.7 eq.), CBr4 (1.7 eq.), DCM, 0 °C, 1.5 hours, then room temperature, 4 
hours, 73 %; d) benzylamine (2.0 eq.), DIPEA (5.0 eq.), acetonitrile, 93 °C, 72 hours, 95 %; e) Pd/C (10 % on charcoal, 
0.05 eq.), H2 (balloon pressure), methanol, 45 °C, 48 hours; f) Boc2O (1.0 eq.) methanol, room temperature, 1 hour, 
73%; g) magnesium powder (8.0 eq.), methanol, ultrasonication, room temperature, 1 hour; h) sodium sulfate 
decahydrate (9.0 eq.), diethyl ether, room temperature, 1 hour; i) oxalic acid 50 (0.5 eq.), diethyl ether, ethanol, 70 %. 
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Our next strategy based on docking studiesa was design of irreversible inhibitors that may 
selectively target the isoform PI3Kα or PI3K, avoiding the inhibition of PI3Kγ, by introducing a 
linker strategy. 
 
Amination of compound (74) with 1-Boc-piperazine in presence of diisopropylethylamine and 
anhydrous acetonitrile as a solvent under reflux at 84 °C for 22 hours gave intermediate (75). By 
Boc deprotection in trifluoroacetic acid/methylene chloride (3:2) solution at room temperature for 2 
hours was obtained compound (76), which has been added to the compound (25) in presence of 
K2CO3 and DMF to yield the compound (77). After deprotection of the N-phthalimide with 
hydrazine monohydrate in ethanol by refluxing at 100 °C (Gabriel synthesis) acrylic anhydride has 
been added to the primary amine containing compound (78) to yield the final product (79) (Scheme 
12), a possible irreversible inhibitor of PI3K (targeting Cys-862) or PI3K (targeting Lys-841) or 
both of them (Figure 22). 
 
Firstly the activity of these potential covalent compounds has been determined by using in cell 
Western inhibition assay and in vitro PI3K Kinase Glo assay. Compounds NCB144 (81) and 
NCB145 (82) have been identified as highly active inhibitors in melanoma cells (Table 9). 
Additionally, very good cellular inhibitor activity has been noticed by compound NCB147 (83) 
(Table 9). Chloracetamid containing compound NCB141 (80) showed low inhibitor activity. Very 
good cellular inhibitor activity was also achieved by a spirocyclic compound GSA100 (62) (Table 
10). 
 
High cellular activity was accomplished by compound NCB152 (79) (Table 11). Also very good in 
vitro activity for PI3K led to a conclusion that NCB152 (79) could be an irreversible inhibitor of 
PI3K. Further cellular, chemical genetics as well as protein mass spectrometry experiments are 
on-going to confirm the covalent bond modification of Cys-862 by PI3K by using the compound 
NCB152 (79). 
 
 
 
 
 
 
a Docking studies are computational techniques for the exploration of the possible binding modes of a substrate to a 
given receptor, enzyme or other binding site. 
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Scheme 12. Reagents and conditions: a) N,N-diisopropylethylamine (1.0 eq.), 1-Boc-piperazine (1.0 eq.), anhydrous 
CH3CN, reflux under argon at 84 °C for 22 hours, 64 %; b) trifluoroacetic acid/methylene chloride (3:2) (25 ml), 2 
hours at room temperature; c) compound (25) (1.0 eq.), 2-(2-(piperazin-1-yl)ethyl)isoindoline-1,3-dione (76) (1.7 eq.), 
K2CO3 (3.2 eq.), DMF, 2 hours at room temperature; d) hydrazine monohydrate (421 mol, 1.1 eq.), EtOH, reflux at 
100 °C for 5 hours, than conc. HCl (91.4 μl) was added and further reflux for 1 hour; e) N,N-diisopropylethylamine (1.1 
eq.), acrylic anhydride (1.0 eq.), CH2Cl2, 2 hours at room temperature, 47 %. 
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Table 11. Inhibitor activitya  
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R2 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB152) 79 
 
20 5.45 ± 1.74 16.27 ± 0.96 47.18 ± 4.08 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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Figure 23. Presented is cellular activity (pPKB/PKB, pS6 on A2058 and pS6 on TSC2-/-MEFs) at 1 μM and in vitro 
activity against PI3K at 200 nM; the lower the bar chart the better is the activity of the relevant compound. 
 
 
Compounds (84-87) (Table 12) are synthesized in the same way as already presented in (Scheme 9). 
They showed low activity in vitro and in vivo experiments. Replacement of difluoromethyl group 
with methyl group led to a strong reduction in inhibitor activity due to loss of hydrogen bond 
formation between fluorine atom and catalytic Lys-833 in ATP pocket of PI3Kγ isoform. Also, a 
lack of the fluorine effect should not be ignored. Fluorine increases the lipophilicity of a given 
inhibitor which leads to a better cellular permeability. The better is inhibitor permeability the higher 
is its concentration within the cell and therefore better inhibition of PI3K. 
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Table 12. Inhibitor activitya  
N
N
N
N
NN
N
O
N
H3CR
3
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R3 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB133) 84 
 
24 80.46 ± 1.69 90.46 ± 5.76 106.74 ± 0.92 
(NCB134) 85 
 
36 68.13 ± 0.07 80.29 ± 4.39 120.91 ± 0.15 
(NCB130) 86 
 
22 67.92 ± 1.23 89.02 ± 4.04 100.83 ± 0.93 
(NCB135) 87 
 
45 52.61 ± 19.06 63.14 ± 0.03 127.59 ± 7.51 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
 
 
Further biological examinations have also done on bone marrow derived mast cells (BMMC). It 
was quantificated the inhibition of Thr308 phosphorylation (in PKB) normalized to the signal of 
adenosine (Ade) stimulated cells without inhibitor treatment. Experiments were repeated four times 
for two different concentrations of inhibitors (1.0 μM and 0.1 µM). They indicated that our 
inhibitors inhibit quit well PI3Kγ signalling in mast cells (Figure 24, Table 13). The next step is to 
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determine whether these inhibitors are highly specific for PI3Kγ and whether they indeed bind 
covalently. 
 
Further experiments with Wortmannin, which is a covalent ATP competitive inhibitor, confirmed 
that our inhibitors are capable to compete for the binding with PI3Kγ (Figure 25). Then, covalent 
binding was tested by coupling the PI3Kγ to beads, which can be recovered by sedimentation what 
allowed washing away of the inhibitors if they are not covalently linked to PI3Kγ. If, after several 
washing steps of the beads, Wotmannin (which was added after the washing steps) is still unable to 
bind to PI3K, it is a good indication that the covalent binding of our designed inhibitors exists 
(Figure 25). The positive results in this experiment were obtained in case of bromoacetamid 
containing NCB144 (81) and iodoacetamid containing NCB145 (82). 
 
Anyway, in order to confirm these results (covalent binding and PI3Kγ specificity) more biological 
experiments should be done. Our next goal is to show that our potential covalent binders NCB144 
(81) and NCB145 (82) for PI3Kγ do not bind covalently to others PI3Ks so we could significantly 
reduce inhibitor concentration in long time treatments of the cells. 
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Figure 24. Presented is cellular activity against PI3Kγ in bone marrow derived mast cells (BMMC) at 1.0 and 0.1 µM; 
the lower the bar chart the better is activity of the relevant compound. 
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Table 13. Inhibitor activitya 
N
N
N
N
NN
N
O
N
F
FR
 
 
BMMC inhibition 
Compound R Stimulus 
 1 μM 0.1 μM 
DMSO  PBS 0.13   
DMSO  Ade 1.00   
(NCB141) 80 
 
Ade  0.16 0.68 
(NCB144) 81 
 
Ade  0.18 0.73 
(NCB145) 82 
 
Ade  0.15 0.59 
(NCB147) 83 
 
Ade  0.33 0.69 
(GSA100) 62 
 
Ade  0.09 0.50 
aInhibitor efficacy was measured by in cell Western inhibition assay on bone marrow derived mast 
cells (BMMC) at two concentration 1.0 and 0.1 µM; the smaller the value, the stronger is the 
inhibition. 
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Figure 25. Competition and Covalent binding assay present weather the inhibitors compete with wortmannin for 
binding to the catalytic center of PI3Kγ and weather they bind covalent to the PI3Kγ. The weaker the signal for 
wortmannin the better is inhibitor. Experiments were done two times with different concentration of wortmannin of 100 
nM and 200 nM. The covalent binding can be noticed by compounds NCB144 (81) and NCB145 (82). 
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4.3. PI3K Inhibitor Activity against Human Glioblastoma 
 
Glioblastoma multiforme (GBM) is the most common and most malignant of the primary brain 
tumors and usually spreads quickly to other parts of the brain. For this reason, these kinds of tumors 
are difficult to treat and it is not uncommon for them to recur after initial treatment. Unfortunately, 
prognosis for patients with high-grade gliomas is generally poor, less than 12 months survival after 
diagnoses. The care of GBM is usually multidisciplinary and involves chemotherapy, radiation, 
radiosurgery, antiangiogenic therapy, and surgery [61]. Difficult treatment of glioblastoma is due to 
several complicating factors such as [62]:  
 The tumor cells are very resistant to other conventional therapies 
 The brain is susceptible to damage due to conventional therapy 
 The brain has a very limited capacity to repair itself 
 Many drugs can not cross the blood-brain barrier to act on the tumor (A physiological 
mechanism that alters the permeability of brain capillaries, so that some substances, such as certain 
drugs, are prevented from entering brain tissue, while other substances are allowed to enter freely). 
 
 
Figure 26. Positron emission tomographies (PET) scan of glioblastoma multiforme [61]. 
Therefore there is a need for novel and improved approaches that will be more efficient than 
conventional therapies. Since GBM tumors have developed the mechanisms of treatment resistance, 
monotherapy would not be the most effective method to treat these kinds of tumors [63].  
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 66
 
                                                
One of the promising targets for such an approach is the PI3K/Aktb pathway. Deregulation in PI3K-
mediated signaling network plays a central role in formation of variety of tumors, including GBM 
[65]. PI3K and Akt are also involved in the activation of mTOR, which plays important role in 
regulating protein synthesis and cell growth. According to important role of this pathway, glioma 
cell lines were treated against of differ PI3K inhibitors, showing that inhibition of p110 is 
effective in blocking of proliferation. Evan better results were obtained in case of dual inhibition of 
PI3K and mTOR as well [66]. It was also shown that inhibition of PI3K sensitizes GBM to 
chemotherapy and to death receptor-induced apoptosisc [67].  
 
A dual PI3K/mTOR inhibitor PI-103 (11) was considered as promising candidate for treatment of 
GBM, because of its ability to selectively block p110 and mTOR at nanomolar concentrations 
[35]. PI-103 (11) has an anti-proliferative effect on GBM cells and efficiently sensitizes them for 
chemotherapy induced apoptosis. It was also concluded that PI-103 (11) in concurrent treatment 
with chemotherapeutic drugs had better effect on increasing of apoptosis and reducing of colony 
formationd compared with chemotherapy treatment alone. These results suggested that PI3K 
inhibitors used together with traditional therapies that have been insufficient to treat GBM, can 
restore cell’s ability to undergo apoptosis [68]. 
 
 
 
 
bThe serine/threonine protein kinase Akt, also known as protein kinase B (PKB) or RAC-PK, was initially identified as 
one of the downstream targets of phosphatidylinositol-3 kinase (PI3K). Akt kinase pathway is one of the most actively 
studied pathways in drug development research. Activated Akt plays important role in mediating signals for cell 
growth, cell survival, cell-cycle progression, differentiation, transcription, translation, and glucose metabolism. 
 
cApoptosis or programmed cell death is defined as a mechanism of cellular suicide which occurs after sufficient cellular 
damage. The end result of apoptosis is cell death without inflammation of the surrounding tissue. 
dA colony is population of a single type of microorganism that is growing on a solid or semi-solid surface. Bacteria, 
yeast, fungi, and molds are capable of forming colonies. Indeed, when a surface is available, these microbes prefer the 
colonial mode of growth rather than remaining in solution. On a colonized solid surface, such as the various growth 
media used to culture microorganisms, each colony arises from a single microorganism. The cell that initially adheres to 
the surface divides to form a daughter cell. Both cells subsequently undergo another round of growth and division. This 
cycle is continually repeated. After sufficient time, the result is millions of cells piled up in close association with each 
other. This pile, now large enough to be easily visible to the unaided eye, represents a colony. 
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Recently, it was reported that high cellular and in vivo activity of a novel PI3K inhibitor, PX-866 
(88), against human glioblastoma. PX-866 (88) is irreversible, biologically stable synthetic viridin 
derivative (structure related to wortmannin 1). Inhibition is based as by wortmannin (1) on covalent 
binding to Lys-802 in PI3K (more potent than wortmannin 1) and Lys-883 in PI3Kγ. Also, PX-
866 (88) inhibits PI3K isoform and is weak inhibitor of PI3Kβ. Investigation of this inhibitor in 
glioblastoma cell lines after treatment of 72 hours resulted in dose-dependent growth inhibition. It 
was concluded that PX-866 (88) is directly involved in inhibition of invasion and angiogenice 
potential of glioblastoma cells and also was found its therapeutic activity in human tumor xenograft 
models [69]. 
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Figure 27. Chemical structure of PI3K inhibitor: PX-866 (88) [70]. 
 
As understanding of glioma biology has progressed, there is a hope that further efforts will lead to 
more effective, less toxic and rationally conceived therapeutics that target specific genes or proteins 
and that in combination with radio or chemo therapy will overcome various obstacles so far present. 
Since recent studies have implicated PI3K/Akt and mTOR pathway in pathogenesis of glioblastoma 
as well as other types of gliomas cancers, we tested our most active PI3K/mTOR inhibitors against 
human glioblastoma cell lines. Experimental results will be described in the following chapter. 
 
 
 
                                                 
e Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels. 
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing. However, it is also 
a fundamental step in the transition of tumors from a dormant state to a malignant one, by supplying them with oxygen 
and nutrients required for their growth and expansion into the surrounding tissue. 
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4.3.1. PI3K Inhibitor Efficacy in Colony Formation Assay on Malignant Glioma 
Cell Lines 
 
The effect of PI3K inhibition in the glioma cell lines LN18, LN215 and U343 was analyzed using 
colony formation assay. In a colony formation assay, both the number and size of colonies formed 
after 14 days of drug treatment were measured. Among the first group of tested PI3K inhibitors 
(Figure 28 and Table 14), ZSTK474 (38) and its pyrimidine derivative NCB35 (90) significantly 
reduced colony formation in GBM cell lines tested compared with the untreated control. Quite well 
reduction was also noticed by triazine derivative NCB5 (89). Therefore, the next round of testing 
was focused on further ZSTK474 derivatives. Unfortunately, these experimental results are not 
finished until the submission date of my thesis. 
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Figure 28. Presented is PI3K inhibition with various PI3K/mTOR inhibitors by reducing the colony formations of 
LN18, LN215 and U343 malignant glioma cell lines; the smaller the chart bar the better is inhibition. 
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Table 14. Inhibitor activitya 
LN18 
Cell line 
LN215 
Cell line 
U343 
Cell line 
Compound Structure 
1 μM 1 μM  1 μM 
CTRL DMSO 131.0 ± 21.2 37.0 ± 0.0 95.5 ± 4.9 
(NCB5) 89 N
N
N
N
N
O
O
N
CF3
NH2  
129.5 ±  21.9 39.5 ± 0.7 12.5 ± 3.5 
(NCB35) 90 
N
N
NN
N
N
FF
O
O
17.0 ± 7.1 10.5 ± 6.4 0.0 ± 0.0 
(NCB38) 38 97.5 ± 0.7 31.5 ± 9.2 2.5 ± 3.5 
(MJA40) 91 
 
97.5 ± 60.1 33.0 ± 5.6 37.5 ± 3.5 
(JBA65) 92 
 
118.0 ± 2.8 33.5 ± 6.4 17.5 ± 3.5 
aInhibitor efficacy was measured by in Colony formation assay on malignant glioma cell lines
LN18, LN215, U343; the smaller the value, the stronger is the inhibition. 
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4.4. Triazine and Pyrimidine Derivatives 
 
 
Figure 29. Presented is a strategy where the fragments of the known biologically active chemical compounds are 
crossed between each other, with the aim to obtain novel so-called hybrid-molecules. This offers the potential to modify 
existing leads in terms of selectivity, pharmacokinetic properties or side-effect profile. Novel hybrid molecules can be 
crossed with compounds obtained by crossing of two other PI3K inhibitors, with the aim to gain second generation 
hybrid molecules. In this example the chemical space of molecules PI-103 and ZSTK474 was rationally extended by 
applying scaffold hybriding and scaffold hopping strategies at the same time to provide novel molecules that are not 
covered by pharmaceutical industry and for which interesting biological properties where obtained. In comparison with 
the medicinal chemistry examples from the literature, where whether hybriding or hopping was obtained on a certain 
single scaffold, we obtained both strategies in a combinatorial way on several different scaffolds  
 
Due to ZSTK474 (38) excellent anti tumour activity with low toxicity, triazine scaffolds are of great 
interest in PI3K research. In order to extend chemical space of ZSTK474 (38) in rational way we 
applied scaffold hybriding and scaffold hopping strategies at the same time to provide novel 
molecules that are not covered by pharmaceutical industry with interesting biological properties 
(Cmiljanovic V. unpublished). 
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4.4.1. Chemistry and Biology of Di-Morpholine-Containing Triazine and 
Pyrimidine Derivatives 
 
 
 
Scheme 13. Reagents and conditions: a) cyanuric chloride (1.0 eq.), morpholine (4.5 eq.), DMF, 0 °C, 20 minutes, 
56%; b) boronic acid pinacol ester (4.0 eq.), 1,2-dimethoxyethane:2M Na2CO3 (3:1), dichloro 1,1’-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 – 20 hours; 
c) amine (1.1 eq.), DMF, NaH (60% in mineral oil, 1.5 eq.) added at 0 °C, 30 minutes at room temperature, than reflux 
at 153 ° C for 3.5 – 5.5 hours, 13–77 %. 
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Table 15. Inhibitor activitya  
N
N
N
N
N R
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(GSA10) 
96  
77 61.63 ± 5.22 115.25 ± 15.90 106.64 ± 0.21 
(NCA197) 
97  
68 119.87 ± 18.25 112.51 ± 3.16 102.17 ± 0.89 
(NCA201) 
98  
87 119.10 ± 6.51 132.37 ± 7.62 85.45 ± 0.18 
(NCA193) 
99  
82 121.19 ± 19.07 74.42 ± 0.95 88.29 ± 0.37 
(NCA189) 
100  
76 111.31 ± 2.12 77.41 ± 4.32 61.35 ± 2.29 
(NCA183) 
101  
26 41.11 ± 5.37 24.12 ± 2.12 65.29 ± 4.95 
(NCA205) 
102 
N
 
60 84.14 ± 1.28 109.92 ± 3.33 79.70 ± 1.48 
(NCB9) 
103  
97 99.13 ± 9.83 102.43 ± 3.00 127.46 ± 2.04 
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Table 15. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R In vitro PI3Kα200nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB90) 
104  
77 76.90 ± 4.15 78.29 ± 8.00 71.30 ± 2.63 
(NCB89) 
105  
99 84.40 ± 7.90 105.60 ± 1.18 107.76 ± 3.36 
(NCA215) 
106 
 
97 128.77 ± 13.96 126.85 ± 7.06 79.24 ± 0.46 
(NCA163) 
107  
67 90.95 ± 21.64 30.03 ± 1.51 11.71 ± 2.32 
(NCB5/NCB63) 
89  
20 8.31 ± 3.13 25.75 ± 5.92 17.57 ± 0.95 
(MJA47) 
108  
121 96.82 ± 5.81 74.93 ± 1.30 101.63 ± 6.10 
(NCB78) 
109 N
N
 
72 78.19 ± 2.92 105.67 ± 10.89 86.69 ± 8.52 
(NCB15) 
111  
11 23.08 ± 3.07 20.71 ± 1.06 11.56 ± 2.81 
(NCB86) 
112  
8 16.29 ± 7.72 42.32 ± 4.07 39.77 ± 3.51 
(NCB127) 
113  
5 2.87 ± 10.60 26.42 ± 2.29 42.42 ± 2.38 
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Table 15. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R In vitro PI3Kα200nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(MJA7) 
114 N
H  
79 36.99 ± 1.59 34.15 ± 4.37 14.14 ± 3.75 
(VVA81) 
115 N
H
CF3
 
100 90.63 ± 0.66 137.00 ± 4.78 73.79 ± 1.92 
(MJA6) 
116  
110 73.21 ± 5.03 65.29 ± 5.79 91.55 ± 1.48 
(MJA46) 
117 N
H
N
 
38 44.13 ± 2.32 72.60 ± 2.31 53.40 ± 6.74 
(VVA103) 
118 
 
37 91.12 ± 11.38 168.23 ± 6.46 88.09 ± 6.42 
(VVA97) 
119 
 
26 45.77 ± 2.00 142.64 ± 19.21 70.19 ± 0.77 
(NCB22) 
120  
111 68.71 ± 6.61 86.46 ± 3.36 97.61 ± 0.42 
(MJA14) 
121  
119 93.33 ± 6.38 59.95 ± 2.66 99.16 ± 0.38 
(MJA44) 
122  
61 57.72 ± 3.91 77.53 ± 0.32 78.99 ± 3.86 
(BAS01056850) 
123  
77 64.41 ± 4.01 103.79 ± 0.13 85.27 ± 2.54 
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Table 15. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R In vitro PI3Kα200nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(MJA12) 
124  
116 107.02 ± 1.20 88.20 ± 4.84 97.58 ± 2.59 
(MJA32) 
125 
N
O
 
126 96.59 ± 9.01 125.71 ± 4.19 95.15 ± 0.30 
(ASN09891537) 
126 
 
128 95.69 ± 4.21 102.09 ± 4.09 104.33 ± 0.38 
(BAS07354380) 
127  
103 65.32 ± 7.97 98.41 ± 5.85 ND 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue – no activity, green – low 
activity, red – good activity, orange – very good activity. 
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Scheme 14. Reagents and conditions: a) morpholine (2.5 eq.), N,N-diisopropylethylamine (3.0 eq.), ethanol, 0 °C to 
room temperature, 16 hours, mixture of (129) and (131) (7:1); b) dichloro 1,1’-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 – 20 hours; c) amine (1.1 eq.), NaH (1.5 eq.), 
DMF, 153 °C, 4 - 5 hours. 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 77
 
 
Table 16. Inhibitor activitya  
N
N
N
N R1
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R1 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(GSA20) 
133  
78 74.04 ± 14.02 107.14 ± 2.02 96.57 ± 3.71 
(NCA195) 
134  
85 157.28 ± 13.05 143.66 ± 6.36 88.98 ± 3.51 
(NCA199) 
135  
97 146.71 ± 36.93 120.45 ± 1.13 107.80 ± 5.29 
(NCA191) 
136  
73 143.05 ± 0.53 95.23 ± 0.98 95.69 ± 0.48 
(NCA187) 
137  
87 126.68 ± 13.33 71.21 ± 4.76 77.90 ± 11.04 
(NCA185) 
138  
57 90.82 ± 16.12 56.23 ± 1.99 56.53 ± 4.28 
(NCA203) 
139 
N
 
75 109.10 ± 26.09 97.56 ± 6.74 97.23 ± 7.99 
(NCB11) 
140 
N
F  
117 87.88 ± 6.55 105.63 ± 3.28 109.70 ± 0.28 
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Table 16. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R1 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCA207) 
141  
93 117.11 ± 10.86 98.41 ± 7.24 94.96 ± 7.48 
(ASA89) 
142 
 
123 97.76 ± 1.58 91.09 ± 1.10 99.26 ± 5.61 
(NCA165) 
143  
51 132.28 ± 1.49 38.33 ± 0.60 41.10 ± 4.80 
(NCA235) 
144  
15 23.74 ± 7.03 67.78 ± 9.09 32.31 ± 7.20 
(GSA28) 
145  
60 74.78 ± 30.58 115.15 ± 5.44 120.74 ± 9.79 
(NCB16) 
146  
18 33.68 ± 1.06 41.78 ± 0.60 7.84 ± 2.31 
(NCB115) 
147  
30 14.34 ± 7.90 76.72 ± 16.53 83.58 ± 0.80 
(ND) 
148  
ND ND ND ND 
(NCB20) 
149 N
H  
86 49.07 ± 1.46 67.19 ± 1.39 96.16 ± 3.56 
(NCB19) 
150  
105 70.50 ± 3.42 57.22 ± 10.09 47.11 ± 1.58 
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Table 16. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R1 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(GSA21) 
151 N
H
N
 
46 57.25 ± 5.63 96.08 ± 4.21 85.71 ± 1.83 
(ASA87) 
152  
105 80.54 ± 5.08 88.73 ± 1.84 99.14 ± 1.08 
(ASA88) 
153  
114 71.55 ± 1.31 90.95 ± 0.45 104.60 ± 6.17 
(NCA169) 
146  
63 87.15 ± 7.02 67.68 ± 5.36 103.83 ± 2.08 
(GSA29) 
154  
64 106.20 ± 7.66 107.60 ± 5.97 87.78 ± 0.77 
(ND) 
155  
ND ND ND ND 
(NCA171) 
156  
66 137.28 ± 3.46 74.66 ± 3.65 93.03 ± 0.46 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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Table 17. Inhibitor activitya  
N
N
N
N R2
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R2 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(GSA22) 
157  
87 130.19 ± 11.15 116.52 ± 3.59 122.11 ± 8.76 
(GSA23) 
158  
93 111.26 ± 7.47 108.52 ± 3.62 87.94 ± 0.50 
(GSA24) 
159  
84 104.40 ± 6.52 111.28 ± 5.70 98.18 ± 4.37 
(VVA105) 
160  
30 62.15 ± 2.97 112.42 ± 0.01 51.94 ± 7.30 
(VVA107) 
161 
N
 
81 65.41 ± 14.93 63.24 ± 2.78 113.79 ± 2.88 
(VVA111) 
162  
63 35.61 ± 2.61 22.08 ± 2.06 13.09 ± 1.49 
(VVA109) 
163 N
N
 
72 39.15 ± 1.22 66.39 ± 4.68 98.66 ± 2.06 
(VVA113) 
164  
49 29.78 ± 0.07 63.10 ± 0.99 62.24 ± 4.64 
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Table 17. Continued  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R2 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(VVA131) 
165  
24 33.21 ± 0.94 24.81 ± 10.44 112.90 ± 7.47 
(ND) 
166  
ND ND ND ND 
(VVA119) 
167 
 
98 41.78 ± 6.61 15.40 ± 2.62 37.47 ± 2.39 
(VVA123) 
168  
91 45.83 ± 8.24 19.33 ± 13.69 59.35 ± 3.33 
(VVA117) 
169 
 
42 36.31 ± 0.81 24.14 ± 6.68 75.14 ± 4.77 
(VVA115) 
170  
97 54.17 ± 2.69 34.29 ± 6.07 85.89 ± 12.86 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
 
 
 
 
 
 
 
Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer 
Natasa Cmiljanovic 82
 
 
 
 
 
Scheme 15. Reagents and conditions: a) morpholine (2.5 eq.), N,N-diisopropylethylamine (3.0 eq.), ethanol, 0 °C to 
room temperature, 16 hours; b) amine (28.3 eq.), 80 °C – 120 °C, for 1–21 hours. 
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Table 18. Inhibitor activitya  
N
N
N
N R3
O
O  
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R3 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(ASA102) 
174  
107 64.82 ± 1.28 120.92 ± 2.02 120.21 ± 8.34 
(ASA108) 
175 
N
O
 
107 58.52 ± 0.16 113.26 ± 2.75 111.69 ± 2.48 
(ASA110) 
176  
123 102.52 ± 8.91 127.21 ± 4.04 75.22 ± 0.26 
(ASA109) 
177  
117 98.77 ± 3.45 124.52 ± 2.41 97.40 ± 5.23 
(ASA111) 
178 
N
NH  
134 95.64 ± 5.21 119.60 ± 2.53 129.61 ± 5.28 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured 
by Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red - 
good activity, orange - very good activity. 
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Scheme 16. Reagents and conditions: a) K2CO3 (1.74 eq.) and amine (0.9 eq.) added at -5 °C in solution of 2,4,6-
trichloropyrimidine (179) (1.0 eq.) in DMF, stirred for 30 minutes at same temperature and then over night at room 
temperature; b) K2CO3 (2.8 eq.) and morpholine (1.0 eq.) added at -5 °C in solution of intermediate (181), stirred for 30 
minutes at same temperature and then over night at room temperature; c) morpholine (28.3 eq.), 80 °C, 1 - 1.5 hours. 
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Table 19. Inhibitor activitya  
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibitionCompound R4 In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB106) 
183  
53 38.44 ± 8.11 99.63 ± 11.79 80.29 ± 3.79 
(NCB35) 
90 N
N
CHF2
 
11 8.23 ± 0.85 13.23 ± 0.37 22.81 ± 3.31 
(NCB34) 
184  
36 33.26 ± 2.81 82.25 ± 4.21 77.55 ± 5.87 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller the 
value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - low 
activity, red - good activity, orange - very good activity. 
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4.4.2. Chemistry and Biology of Linked Triazine and Pyrimidine Derivatives 
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N
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Scheme 17. Reagents and conditions: a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 minutes, 28%; b) 2-pyridylcarbinol 
(1.4 eq.), NaH (1.0 eq.), THF, room temperature, 2 hours; c) dichloro 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 - 20 hours; d) amine (1.1 eq.), NaH (1.5 eq.), 
DMF, 153 °C, 4 - 5 hours. 
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Table 20. Inhibitor activitya  
N
N
N
N
O R
O
N
 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R In vitro PI3Kα200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(NCB107) 
189  
86 138.07 ± 12.35 113.19 ± 5.13 106.66 ± 2.10 
(NCB108) 
190  
87 55.36 ± 12.57 116.60 ± 15.21 97.90 ± 5.21 
(NCB109) 
191  
88 100.19 ± 12.24 94.74 ± 4.59 87.17 ± 10.53 
(MJA43) 
192  
51 43.86 ± 0.45 74.76 ± 1.49 104.80 ± 1.00 
(MJA39) 
193 
N
 
91 57.14 ± 0.79 92.21 ± 0.59 105.93 ± 1.67 
(MJA38) 
194  
76 56.74 ± 4.59 104.50 ± 7.80 103.98 ± 5.17 
(GSA33) 
(HGA1) 
195 
N
N
 
89 74.21 ± 20.31 107.08 ± 9.85 106.68 ± 1.64 
(MJA37) 
196  
45 75.02 ± 5.61 84.14 ± 4.08 84.29 ± 9.41 
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Table 20. Continued 
A2058 cell inhibition TSC2-/-MEFs cell inhibition  
Compound R 
In vitro PI3Kα
200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(MJA40) 
197 
 
65 11.79 ± 0.10 44.81 ± 1.23 20.69 ± 2.06 
(VVA77) 
198 
 
99 91.18 ± 4.68 151.85 ± 5.02 82.12 ± 1.06 
(MJA42) 
199  
107 68.70 ± 3.80 77.08 ± 8.16 64.88 ± 0.78 
(MJA60) 
200 
 
84 96.71 ± 5.30 73.21 ± 15.57 115.24 ± 1.64 
(VVA101) 
201 
 
103 112.93 ± 3.16 166.84 ± 13.02 73.96 ± 5.92 
(VVA95) 
202 
 
100 109.80 ± 4.55 159.73 ± 15.04 86.48 ± 2.31 
(MJA41) 
203  
100 64.07 ± 0.51 87.51 ± 3.84 96.01 ± 2.41 
(GSA31) 
(HGA2) 
204 
 
90 111.22 ± 0.53 46.84 ± 2.06 44.42 ± 13.60 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured 
by Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red - 
good activity, orange - very good activity. 
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Scheme 18. Reagents and conditions: a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 minutes; 28 %; b) 2-picolylamine 
(1.1 eq.), CH2Cl2, room temperature, 21 hours; c) 3-picolylamine (1.5 eq.), CH2Cl2, -5 °C, 16 hours; d) dichloro 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 - 20 hours. 
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Table 21. Inhibitor activitya 
N
N
N
N
N
H
R1
O
X
Y
 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibition Compound R1 X Y 
In 
vitro 
PI3Kα
200nM pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(MJA25) 
209  
N C 66 67.88 ± 4.06 118.21 ± 5.83 117.05 ± 2.25
(MJA29) 
210  
N C 123 96.93 ± 1.08 151.32 ± 8.00 83.13 ± 4.17
(MJA30) 
211  
N C 71 79.64 ± 1.53 140.29 ± 5.92 75.74 ± 5.17
(MJA31) 
212  
N C 40 76.44 ± 1.14 62.76 ± 1.67 79.32 ± 16.15
(MJA28) 
213 N
H  
N C 104 74.61 ± 0.57 142.57 ± 8.80 76.63 ± 0.04
(MJA26) 
214  
N C 123 90.19 ± 0.74 129.13 ± 3.29 77.38 ± 0.76
(MJA27) 
215  
N C 125 97.83 ± 0.33 148.24 ± 10.02 73.45 ± 7.96
(GSA59) 
(HGA13) 
216  
C N 98 99.92 ± 3.62 120.50 ± 13.46 94.71 ± 4.22
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Table 21. Continued 
A2058 cell inhibition 
TSC2-/-
MEFs cell 
inhibition Compound R1 X Y 
In 
vitro 
PI3Kα
200nM pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(HGA14) 
217  
C N 67 105.56 ± 15.25 119.55 ± 20.19 99.75 ± 2.11
(HGA15) 
218  
C N 19 80.92 ± 7.78 117.41 ± 4.39 91.39 ± 0.61
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition 
assay on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was 
measured by Kinase Glo assay and given numbers represent % remaining activity, the smaller 
the value, the stronger is the inhibition; coloured numbers represent: blue - no activity, green - 
low activity, red - good activity, orange - very good activity. 
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Scheme 19. Reagents and conditions: a) 2-pyridinemethanol (1.0 eq.), NaH (1.0 eq.), THF, room temperature 3 hours; 
b) morpholine (1.5 eq.), N,N-diisopropylethylamine (1.5 eq.), dioxane, room temperature, 2 hours, c) dichloro 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 - 20 hours. 
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Table 22. Inhibitor activitya 
 
A2058 cell inhibition TSC2-/-MEFs cell inhibition 
Compound R2 In vitro PI3K200 nM 
pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(JBA155) 
223  
124 92.46 ± 7.84 93.57 ± 12.43 111.78 ± 0.90 
(JBA153) 
224  
127 92.10 ± 15.18 74.02 ± 1.70 99.96 ± 1.22 
(JBA139) 
225  
31 54.80 ± 3.93 84.43 ± 1.35 104.26 ± 3.51 
(JBA157) 
226 
N
 
109 104.73 ± 0.22 80.52 ± 0.15 104.67 ± 0.76 
(JBA151) 
227  
66 75.40 ± 8.44 93.72 ± 3.60 92.87 ± 2.84 
(JBA149) 
228  
19 64.73 ± 14.65 64.75 ± 2.99 108.29 ± 9.43 
(NCB21) 
229  
84 83.90 ± 3.86 71.67 ± 7.66 85.98 ± 1.42 
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aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay 
on melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured 
by Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red - 
good activity, orange - very good activity. 
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Scheme 20. Reagents and conditions: a) 1-aminomethylpyridine (1.1 eq.), N,N-diisopropylethylamine (1.1 eq.), 
dioxane, room temperature, 2 hours, mixture of JBA113A and JBA113B (2:1); b) JBA113A (1.0 eq.), morpholine (1.8 
eq.), N,N-diisopropylethylamine (1.5 eq.), reflux, 5 hours; c) JBA113B (1.0 eq.), morpholine (1.5 eq.), N,N-
diisopropylethylamine (1.5 eq.), dioxane, room temperature, 2 hours; d) dichloro 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15 - 20 hours. 
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Table 23. Inhibitor activitya 
 
A2058 cell inhibition TSC2-/-MEFs cell inhibition
Compound R3 A B C 
In 
vitro 
PI3Kα
200nM pPKB/PKB 
1 µM 
pS6 
1 µM 
pS6 
1 µM 
(JBA129) 
234  
C N N 103 97.72 ± 5.43 95.73 ± 0.37 98.49 ± 5.99 
(JBA141) 
235  
C N N 62 67.50 ± 6.68 47.41 ± 1.99 85.89 ± 0.69 
(JBA131) 
236  
N C N 88 101.11 ± 22.60 68.84 ± 0.63 109.03 ± 1.23
(JBA143) 
237  
N C N 123 97.95 ± 1.12 110.22 ± 6.70 99.36 ± 2.53 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on 
melanoma cell line A2058 and TSC2-/-MEFs cell line; in vitro PI3K inhibition was measured by 
Kinase Glo assay and given numbers represent % remaining activity, the smaller the value, the 
stronger is the inhibition; coloured numbers represent: blue - no activity, green - low activity, red - 
good activity, orange - very good activity. 
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4.5. Graphical Overview of the Best Di-Morpholine-Containing and Linked 
Triazine and Pyrimidine Derivatives 
In Cell  Western Inhibition and In Vitro Inhibition for PI3Kalpha 
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Figure 30. Presented is cellular activity (pPKB/PKB, pS6 on A2058 and pS6 on TSC2-/-MEFs) at 1 μM and in vitro 
activity against PI3K at 200 nM; the lower the bar chart the better is the activity of the relevant compound. 
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Figure 31. Presented is cellular activity (pPKB/PKB, pS6 on A2058 and pS6 on TSC2-/-MEFs) at 1 μM; the lower the 
bar chart the better is the activity of the relevant compound. 
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In vitro  PI3Kα Inhibition at 200 nM
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Figure 32. Presented is in vitro activity against PI3K at 200 nM; the lower the bar chart the better is the activity of the 
relevant compound. 
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4.6. Crystal Structures of PI3K/mTOR Inhibitors 
We have determined the crystal structures of PI3K in complex with inhibitors ZSTK474 (38), 
NCB36 (48), NCB15 (111), NCB5 (89), MJA40 (91) and ASA76 (for its biological and chemical 
information see the PhD thesis of Dr. Vladimir Cmiljanovic) (Figure 33). All of the compounds 
made the key hydrogen bond through the interaction of morpholine oxygen with the backbone 
amide of the hinge Val-882. The contact list with exact description of amino acids responsible for 
hydrogen bond formations and for hydrophobic interactions is given in table (see page 100). 
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Figure 33. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-F) Surface 
diagram of ATP·PI3K crystal structures zoomed into the ATP-binding site. Amino acids residues and the ligands are 
represented in stick form, colored according to the element (C atoms in grey, N atoms in blue, O atoms in red and S atoms 
in yellow). Numbers denote highlighted, prominent side chains mediating PI3K/ligand interactions; in green are colored 
amino acids for which hydrophobic contacts with the ligand could be obtained. For amino acids such as Asp-836, Asp-841, 
Glu-880, Val-882, Asp-964, Lys-833, and Lys-890 both hydrophobic contacts and H-bridge formations could be obtained. 
Only hydrogen bonds that we are confident with are shown as yellow dashed lines. These correspond to the contact list on 
page 100. For MJA40 there is only density for the morpholino group in contact with Val-882 leading us to the conclusion 
that MJA40 is not able to reach the binding pocket of PI3K; this observation was comparable with the experimental in vitro 
data and with the in silico data by docking MJA40 into PI3K. 
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Figure 34. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-D) 
Extracted amino acids mediating PI3K/ligand interactions within the ATP-binding site; the electron density map of the 
compounds is presented in magenta mesh. Only hydrogen bonds that we are confident with are shown as black dashed 
lines. 
 
The available crystal structures of PI3K and PI3Kα from the Protein Data Bank were used for 
molecular modelling experiments. Three dimensional model of mTOR was created based upon the 
crystal structure of p110. The models were constructed as outlined by Pirola et al. [71]. For the 
docking studies, we used the genetic algorithm application GOLD [72]. Compounds were docked 
into the crystal structures and homology model by optimizing conformational and non-bonded 
contacts. The default scoring functions in GOLD are GoldScore and ChemScore; after an initial 
examination of LY294002 to compare the docked compound in p110 to its X-ray structure, we 
elected to use GoldScore to dock the compounds, which produced nominally better results. 
Compound orientations using GOLD and GoldScore were generated and saved, and the highest-
scoring orientation that also formed plausible hydrogen bond interactions was selected. The docked 
ligand and receptor structures were subsequently subjected to minimization and dynamics using the 
program Yasara and the Yamber forcefield. This was conducted mainly to relieve close contacts 
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within the protein to the ligand, and to determine whether any of the docked compounds would be 
“ejected” from the pocket. Minimization and dynamics cycles were performed until the 
conformations of both the ligand and protein remained unchanged, and none of the docked 
compounds were “ejected”. 
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5. Summary and Outlook 
By reason of phosphatidylinositol-3-kinase (PI3K) signaling pathway implication in multiple 
aspects of tumor genesis as well as other diseases, significant efforts have been invested towards 
developing agents which may inhibit that pathway. These agents (chemical inhibitors) have been 
extremely helpful tools in verifying PI3Ks as therapeutic targets as well as in understanding the role 
of PI3K enzymes in signal transduction and downstream physiological and pathological processes.  
 
Physicochemical properties such as solubility, pharmacokinetic and pharmacodynamic are very 
important alongside potency and selectivity in developing process of a drug candidate suitable for 
clinical estimation. However, great challenges are present in the creation of specific PI3K inhibitors 
due to the sequence and structural similarities of the ATP sites in class I PI3K isoforms. Despite 
these challenges, new inhibitors with surprising selectivity profiles are appearing and helping in 
revealing of structural determinants that control selectivity across the PI3Ks. At the beginning of 
PI3K inhibitor development there was a concern that those inhibitors due to their properties might 
lead to unwanted toxic effects in patients. That was denied by appearance and use of second 
generation of inhibitors in preclinical and clinical examination. Third generation inhibitors have 
been already starting to explore the advantages of isoform selectivity, therefore chemical biology 
and structure-based design approaches should continue to deliver a variety of isoform-specific or 
pan-selective profiles in order to reduce gaps of knowledge about the specific function of different 
PI3K isoforms. 
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6. Experimental Part 
6.1. General Work Conditions 
All reactions were stirred magnetically in oven-dried glassware and when air-sensitive substances 
were used, the reaction was performed under inert gas atmosphere. Anhydrous solvents were 
transferred via syringe or cannula. Acetonitrile, dichloromethane, N,N-diisopropylethylamine, 
dimethoxyethane, dimethylformamide, dioxane, ethanol, methanol, tetrahydrofuran were purchased 
from Fluka or Aldrich in septum sealed bottles. Diethyl ether was used from the solvent system in 
Lab. 023a. Technical grade solvents used for extraction and column chromatography were distilled 
prior to use. Deuterated solvents were purchases from Cambridge Isotope Laboratories and other 
materials and reagents from Fluka, Acros, Aldrich, Anthem Pharmaceutical Research, Boc 
Sciences, Boron Molecular, ChemCollect, Fluorochem, Frontier Scientific, Matrix Scientific, 
Princeton Bio, Strem, Synthonix, TCI Europe or Trylead Chemicals in the highest available grade 
and used without further purification. Analytical thin layer chromatography (TLC) plates from 
Merck were used for reaction control (silica gel 60 on aluminium sheets) and chromatographic 
analyses (silica gel 60 on glass). Silica gel 60 (Fluka) was used for silica gel flash column 
chromatography. 
 
6.2. Conditions of Measurements 
Proton nuclear magnetic resonance (1H NMR) spectra and Carbon-13 nuclear magnetic 
resonance (13C NMR) spectra were recorded on Bruker spectrometers (Avance400: 400 MHz for 
1H and 100 MHz for 13C; Avance DRX500: 500 MHz for 1H and 125 MHz for 13C; Avance 
DRX600: 600 MHz for 1H and 150 MHz for 13C) at ambient temperature in the solvents indicated, 
and referenced to the residual solvent signal: CDCl3 (7.26), DMSO-d6 (2.50) or CD3OD (3.31) for 
1H chemical shifts and CDCl3 (77.0), DMSO-d6 (39.0) or CD3OD (49.0) for 13C chemical shifts. 
Chemical shifts are reported in  (ppm). Coupling constants are reported in Hertz (Hz). The 
following abbreviations are used: s (singlet), s, br (broad singlet), d (doublet), t (triplet), q (quartet) 
and m (multiplet). 13C NMR spectra were routinely run with broadband decoupling. 
 
Mass Spectrometry Electron Ionization (MS-EI) and Fast Atom Bombardment (MS-FAB) 
spectra were recorded on a VG70-250 (EI) and a MAT 312, using 3-nitrobenzyl alcohol as a matrix 
(FAB). Mass Spectrometry Electron Spray Ionisation (MS-ESI) spectra were recorded in 
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methanol on a Finnigan MAT LCQ spectrometer. High Resolution Mass Spectrometry (HR-MS) 
was performed by the mass service at the University of Fribourg (CH). Mass signals are given in 
mass units per charge. The fragments and intensities are given in brackets. 
 
Elemental Analysis (EA) was carried out on a Leco CHN-900 device. The values are given in 
mass percent. 
 
X-ray analysis of intermediate compounds NCA131 and NCA79 are presented by (Figure 35 and 
36). 
 
Figure 35. X-ray images of NCA131 
 
 
Figure 36. X-ray images of NCA79 
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6.3. Biological Methods and Parameters  
6.3.1. In Cell Western High Throughput Screening Assay 
 
In every part the biological results from in cell Western-inhibition high throughput screening assay 
are given in tables with classifications for PI3K and mTOR inhibition activity. Both activities are 
listed with inhibitor concentrations of 1 µM and 10 µM. To determine the inhibition activity, cells 
are incubated with the synthesized inhibitors (dissolved in DMSO). This leads to an inhibition of 
PI3Ks, so that phosphate group transfer to downstream effectors (e.g. PKB or S6) is reduced or 
blocked. Inhibition of PI3K results in non phosphorylated downstream effector PKB and inhibition 
of mTOR in non phosphorylated S6 downstream effector. Specific first antibodies recognize and 
bind selectively to phosphorylated downstream effectors pPKB (Ser473) or pS6 (Ser235/236). Then 
fluorescent labeled secondary antibodies (IRDye800 green) bind specifically to the first ones and 
the emitted fluorescence of these secondary antibodies can be measured. The stronger the 
fluorescence, the higher the concentration of binded first antibodies to phosphorylated downstream 
effectors and the weaker the activity of the inhibitor. 
 
 
 
 
Figure 37: The 96-well-View Plate seen through 800nm wavelength with cells and synthesized inhibitors, which were 
incubated with the secondary antibody IRDye800 (green) for pPKB and pS6 amount. The pPKB/PKB and pS6 control 
windows are an assembly of cells, specific first antibodies and fluorescent labelled secondary antibodies (IRDye800). 
Therefore these control windows are giving the highest possible fluorescent intensity and this measured value is 
normalized to 1. The background windows are only composed of cells and secondary antibodies for pPKB and pS6, 
while no primary antibodies are in the background windows. These windows show undesirable fluorescent signals of 
secondary antibodies reacting directly with the cell. This resulting value is subtracted from the measured values. The 
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first two columns give the fluorescent intensity with a 1µM concentration of the synthesized inhibitor, the third and 
fourth column give the fluorescent light intensity for a 10µM concentration of the same inhibitor. From these two 
values the mean value is formed. In the same concentrations are divided the last four columns for pS6. Compound 
BEZ235 (Novartis) is an excellent PI3K inhibitor and is used as a reference inhibitor. For more accurate results, an 
additional secondary inhibitor for PKB (IRDye680) (red) is used. Through scanning at 600 nm the amount of PKB in 
cells can also be measured and by forming the ratio of pPKB and PKB values, variability due to cell amount can be 
eliminated. For pS6 there no corresponding method found and just the amount of pS6 is measured.  
 
Protocol for Phospho-PKB/PKB Detection on A2058 Melanoma 
 
Inhibitor efficacy was measured by a cell assay employing the following protocol: 
Cells were plated in black 96 well view plates (Packard) 24 hours prior to the experiment. Inhibitor 
or DMSO as control were added to the medium (each sample as duplicates) and incubated for 3 
hours. Para-formaldehyde, 4%, was applied for 20 minutes at room temperature to fix the cells. 
After washing with PBS/ 0.1% Triton/X-100, blocking with 10% goat serum in PBS was done for 1 
hour. On a shaker, antibodies diluted in PBS against pPKB Ser473 (Cell Signalling) and PKB (gift 
from E. Hirsch) or pS6 Ser 235/236 (Cell Signalling) were incubated overnight at 4°C. After 
washing with PBS, secondary antibodies (LI-COR) diluted in PBS were applied at room 
temperature in the dark. Plates were washed with PBS prior to scanning on an Odyssey reader. 
 
Day 0 
1. Plate 80'000 cells /well in a black Packard 96 well ViewPlate. 
2. Pipette with the multi channel pipette 200 µl of cell suspension per well. 
3. Check under the microscope the homogeneity of the plating. 
4. Incubate cells 24 hours 
 
Day 1 
1. Carefully throw away the medium and refill the wells with 100 µl of medium. 
Check under the microscope for cell loss. 
2. Add 1 µl of 100x concentrated DMSO or Inhibitor. 
3. Incubate for 3 hours at 37°. 
4. Add 60 µl para-formaldehyde 10% (final 4%) and incubate at room temperature for 20 minutes. 
5. Wash 3 times 5 minutes with (200 µl) PBS/ 0.1% Triton/X-100. 
6. Block 60 minutes with (100 µl) of 10%FCS in PBS at room temperature. 
7. Incubate over night with 50 µl pPKB Ser473 (1:500) and PKB (1:500) or pS6 Ser 235/236 
(1:500) in PBS at 4°C on a shaker. 
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Day 2 
1. Wash 3 times 5 minutes with PBS. 
2. Incubate 60 minutes with 50 µl secondary antibody anti-rabbit IRDye800 (1:800) and anti-mouse 
IRDye680 (1:500) in PBS at room temperature in the dark on a shaker. 
3. Wash 3 times 5 minutes with PBS. 
4. Read the plate on an Odyssey reader. 
 
Reagents 
 Packard ViewPlate (black) #6005225 
 Anti-Phospho PKB Ser 473 (Cell Signaling cat. 4058) 
 Anti-PKB (gift from E. Hirsch, Torino) 
 Anti-pS6 Ser235/236 (Cell Signaling cat. 4856) 
 Goat anti-Rabbit-IRDye 800 CW (LI-COR cat. 926-32211) 
 Goat anti Mouse- IRDye 680 (LI-COR cat. 926-32220) 
 
The higher the phosphorylation in PKB as measured with the Odyssey scan, the higher the 
pPKB/PKB values were indicating lower strength of inhibition of signalling. Assessment of 
compound permeability was indirectly extrapolated by using this assay. The compounds were 
applied to the apical surface of cell monolayers and compound permeation into the cellular 
compartment could be extrapolated by measuring the inhibition of PI3Ks. 
 
6.3.2. Kinase Glo Luminescent Assay 
 
Reagents and Solutions 
 
Kinase Buffer 
For 20ml: 
200 µl 1 M Tris HCl pH 7.5 (10 mM final concentration) 
60 µl 1 M MgCl2 (3 mM final concentration) 
500 µl 2 M NaCl (50 mM final concentration) 
100 µl 10% CHAPS in H2O (0.05% final concentration) (prepare the day before) 
200 µl 100 mM DTT in H2O (1 mM final concentration) 
18.94 ml H2O 
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Phosphatidylinositol Solution (PI) (2x PI=20 µg/ml) 
L-alpha-phosphatidylinositol (from liver bovine) stock 1 mg/ml in CHCl3 from Sigma Cat# P-2517 
200 µl 1 mg/ml PI are dried with nitrogen gas in glass tube (clean and dry with EtOH before adding 
PI) and resuspended in 200 µl 3% Octylglucoside (prepared in H2O the day before!). Then 9.8 ml of 
kinase buffer is added. The lipids are stored in a glass tube at 4 °C for 2-3 weeks. Final 
concentration per well 10 µg/ml. 
 
ATP Solution (2x ATP=2 µM) 
6.7 µl 3 mM ATP (from Roche cat# 10519979001) in H2O are resuspended in 10 ml of kinase 
buffer. Final concentration per well 1 µM. 
 
PI3K Solution 
PI3Kα EMV BV1075, MW=138kDa, conc. 12,3 µM / 0.32 mg/ml 
PI3Kδ EMV BV1060.1698, MW=134.5kDa, conc. 35.1 µM / 4.72 mg/ml 
 
Dilute the kinases in PI solution at the following concentrations: 
20 nM PI3Kα, final concentration per well 10 nM 
5 nM PI3Kδ, final concentration per well 2.5 nM 
 
Kinase Glo from Promega 
10x10 ml cat# V6712 
 
Procedure 
Pipet 25 µl of the desired PI3K solution in each well of a 96 well plate (white microplate). In 2 
wells add only 25 ml buffer. Add 1 ml of the inhibitors at the following concentrations: 51.2 mM 
(final 2.048 mM), 6.4 mM (final 256 nM), 1.6 mM (final 64 nM), 400 nM (final 16 nM), 100 nM 
(final 4 nM) and 25 nM (final 1nM). Carefully tap at the plate to mix and incubate the plate at room 
temperature for 30 minutes. 
Add 25 µl of the ATP solution per well to start the kinase reaction. Carefully tap at the plate to mix 
and incubate it at room temperature for 30 minutes. 
Then add of 50 µl kinase Glo to start the luciferase reaction. Incubate 10 minutes at room 
temperature and then read the plate with the Syngery 4. 
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6.3.3. In cell Western Inhibition Assay on Bone Marrow Derived Mast Cells 
 
Bone marrow derived mast cells (BMMC) were serum-starved and IL-3 depleted for 3 hours (this is 
to eliminate any pPKB signals in the unstimulated cells) and kept in 24 wells of a 24 well plate (37 
C°, 5% CO2). After 2 hours the inhibitors or DMSO were added to the wells, mixed and incubated 
for another hour. Subsequently cells were stimulated with PBS (first lane) or with Adenosine 
(highly PI3Kgamma specific, for 2 min., 37 °C). Stimulation was stopped on ice, the cells collected, 
washed in PBS and lysed for SDS-PAGE. Proteins were separated by SDS-PAGE, blotted onto 
PVDF membranes. Proteins were then detected by immunological detection. pThr308 reflects PI3K 
activity PKB (total) confirms equal loading of protein in each sample. 
 
6.3.4. Covalent PI3Kγ Inhibitors 
 
Material 
 Recombinant PI3Kgamma-[His6] , 340 ng/ml  (from Romy), remove only from -20°C  
immediately before taking the aliquots, freeze immediately again 
 DMSO 
 Inhibitors dissolved in DMSO (1mM and 0.1mM in DMSO of NCB147, GSA100, NCB145_1, 
NCB141, NCB144_2, NCB38) 
 100mM ATP in H20 
 200µM and 20μM Wortmannin in DMSO 
 1x PBS throughout Experiment 1 or 1x PBS + 0.1% NP-40 throughout the Experiment 2 
 2x and 5x Sample buffer 
 
Experimental Procedure 
 Thaw inhibitors and ATP solution 
 Prepare and label all eppendorf tubes required 
 Adjust Thermoblock to 37°C  
 Fill ice bucket 
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Competition Assay 
 
1. Pipette inhibitors (0.5 μl) or ATP (1 μl) into the labeled 1.5 ml eppendorf tubes and add to 2 
tubes DMSO. 
2. Transfer 500 μl PBS (± 0.1% NP40). 
3. Add 15 μl recombinant, mix. 
4. Distribute 50 μl into the tubes, containing DMSO, inhibitors or ATP, mix. 
5. Lock tubes and place on the Thermoblock, shake for 30 minutes at 37 °C. 
6. Place tubes on ice. 
7. Add to one tube with DMSO only 0.5 μl DMSO (no Wortmannin, required as control). 
8. Add to all the others 0.5 μl Wortmannin (20 μM). 
9. Incubate for 15 minutes on ice and mix every 2 minutes by snipping with the fingers. 
10. Add 10 μl 5x sample buffer and heat to 95 °C for 7 minutes. 
11. Store at -20 °C, or directly perform SDS-PAGE, WB. 
 
Covalent Binding Assay 
 
1. Wash 90 µl Ni-NTA beads (Qaigen) in 1 ml PBS (± 0.1% NP40) for each reaction (thus 9 x 1.5 
ml eppendorf tubes are required). 
2. Pellet Ni-NTA beads by centrifugation (4 °C, 3 minutes, 1000g). 
3. Aspirate supernatant. 
4. Repeat washing step once. 
5. Add 1 ml PBS to the beads. 
6. Add 4.5 µl recombinant PI3Kgamma-[His6] to the tubes. 
7. Pipette inhibitors (10 µl) or ATP (20 µl) into the labeled 1.5 ml eppendorf tubes. Add to 2 tubes 
DMSO. 
8. Mix by inverting several times, so that the beads are equally distributed. 
9. Lock tubes and place on the Thermoblock, shake (1200 rpm) for 45 minutes at 37 °C, remove 
tubes regularly and invert repeatedly to redistribute the beads (avoid sedimentation). 
10. Pellet Ni-NTA beads and the coupled PI3Kgamma-[His6] by centrifugation (4 °C, 3 minutes, 
1000g). 
11. Aspirate supernatant. 
12. Add 1 ml PBS, and invert the tubes several tubes. 
13. Shake for 5 minutes on the Thermoblock (1200 rpm, while Thermoblock cools to 4 °C). 
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14. Repeat these steps (starting from the centrifugation) 3x. 
15. Place tubes on ice. 
16. Add 1 ml PBS to the tubes. 
17. Add to one tube with DMSO only 1 µl DMSO (no Wortmannin). 
18. Add to all the others 1 µl Wortmannin (200 µM). 
19. Incubate for 15minutes on the Thermoblock (now 4 °C, 1200 rpm) and invert tubes regularly as 
before. 
20. Pellet Ni-NTA beads and the coupled PI3Kgamma-[His6] by centrifugation (4 °C, 3 minutes, 
1000g). 
21. Aspirate supernatant. 
22. Add 60 µl 2x Sample buffer. 
23. Heat to 95 °C for 7 minutes. 
SDS-PAGE, WESTERN BLOTTING, IMMUNOLOGICAL DETECTION 
 
Usage of Antibodies 
Anti-Wortmannin (Waldi), 1:2000 in 5% skim milk TBST, 1h, RT 
Goat anti Rabbit- HRP coupled, 1:5000 in 5% skim milk TBST, 1h, RT 
 
 CUTTING OF THE GEL OR THE MEMBRANE BELOW THE 94 kDA MARKER 
STRONGLY REDUCES THE BACKGROUND SIGNAL DUE ELIMINATION OF 
KERATIN BANDS 
 LONG WASHING INTERVALLS ARE HELPFUL FOR NICE FILMS 
 
6.3.5. Colony Formation Assay 
 
For each cell line, 500 cells were plated in duplicates into 25-cm2 cell culture flasks containing 10 
ml of culture medium with 10% FCS with or without different PI3K inhibitors. Cells were grown 
for 14 days at 37°C and 5% CO2. The medium was renewed at day 7. Cells were then fixed with 4% 
formaldehyde in 1x PBS and stained with crystal violet.  
 
Reagents 
 Cell culture media: DMEM (Invitrogen), supplemented with 10% FCS (LabForce) 
 Nunc Flasks Nunclon™Δ with Vent/Close Cap. Cat no: 163371 
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6.4. Crystallization and Inhibitor Soaks 
ΔABDp110γ crystals were obtained by the sitting-drop vapour diffusion method at 17˚C in the 
presence of 16% PEG 4000, 250mM (NH4)2SO4 and 100mM Tris pH7.5. The crystals reached their 
maximum size (0.2 mm × 0.1mm × 0.1mm) in about 10 days.  
 
The inhibitors NCB5, NCB15 and NCB36 were prepared in DMSO and diluted in cryoprotectant 
containing 25% PEG 4000, 15% glycerol, 250mM (NH4)2SO4 and 100mM Tris pH7.5 to a final 
concentration of 1mM. The inhibitors MJA40 was prepared in DMSO and diluted in cryoprotectant 
consisting of 20% PEG 4000, 20% DMSO, 250mM (NH4)2SO4 and 100mM Tris pH7.5 to a final 
concentration of 1mM. The inhibitor in cryoprotectant solution was added to the drop containing 
the crystals in a stepwise manner. The crystals were soaked in the final 1mM inhibitor solution for 3 
hours (MJA40), 4 hours (NCB15, NCB5, NCB36) or 16 hours (ZSTK474). Crystals were then 
transferred to fresh inhibitor in cryoprotectant solution for 30 seconds and flash frozen in liquid 
nitrogen.  
 
6.4.1. Data Collection and Structure Determination 
 
Diffraction datasets were collected at the ESRF beamlines ID23-1 and ID29. Images were 
processed using Mosflm [73] or XDS [74] and scaled with SCALA [75]. 
 
The crystal structure of ΔABDp110γ/NCB5 complex was solved by molecular replacement using 
Phaser [76] with the previously published human ΔABDp110γ as the search model (PDB entry 
1E8Y) and subsequent refined using Refmac [77]. Coot was used to manually build inhibitors in the 
unaccounted Fo-Fc difference electron density within the active site of the map [78]. Initial models 
of the inhibitors were generated using the PRODRG server 
(http://davapc1.bioch.dundee.ac.uk/prodrg) [79]. Refmac refinement was iterated with manual re-
building using Coot until the structure converged. 
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